Document:

EX-10.8

 EXHIBIT 10.8 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE
HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 LICENSE AGREEMENT 

BETWEEN 
 COLD SPRING
HARBOR LABORATORY 
 AND 

ASOTHERA PHARMACEUTICALS, INC. 

This License Agreement (“Agreement”) is made effective as of July 31, 2015 (the “Effective Date”) by and between Cold Spring Harbor
Laboratory, a nonprofit New York State education corporation (“CSHL”) having an office at One Bungtown Road, Cold Spring Harbor, New York 11724 and ASOthera Pharmaceuticals, Inc., a corporation organized and existing under the laws of
Delaware (“ASOthera”), having an office at One Bungtown Road, Cold Spring Harbor, New York 11724. 
 RECITALS 

WHEREAS, ASOthera and CSHL are parties to that certain Option Agreement (“Option Agreement”) dated October 24, 2014 pursuant to which CSHL
granted ASOthera an exclusive option to negotiate to acquire a license to practice certain patents and know-how resulting from research conducted in the laboratory of Dr. Adrian Krainer at CSHL; 

WHEREAS, ASOthera has exercised such option in accordance with the terms of the Option Agreement; 

WHEREAS, consistent with the parties’ rights and obligations pursuant to the Option Agreement, ASOthera desires to obtain from CSHL, and CSHL desires to
grant to ASOthera, a license to practice such patents and know-how in accordance with the terms and conditions of this Agreement; 

NOW, THEREFORE, in consideration of the mutual benefits to be derived hereunder, and intending to be legally bound, the parties agree as follows: 

1. DEFINITIONS 
 1.1 Affiliate means, with respect
to a person or entity, a legal entity that is controlling, controlled by or under common control with that person or entity. For purposes of this Section 1.1, the word “control” means (1) the direct or
indirect ownership of more than fifty percent (50%) of the outstanding voting securities of a legal entity, (2) the right to receive fifty percent (50%) or more of the profits or earnings of a legal entity, (3) the right to determine the
policy decisions of a legal entity, or (4) fifty percent (50%) or greater management control over a legal entity. 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 1.2 Commercially Reasonable Efforts means efforts that would be employed by the relevant party in
connection with researching, developing, and commercializing its own products of similar market potential at a similar stage of product life, taking into account the apparent attributes of the product, the competitiveness of the relevant
marketplace, the proprietary positions of third parties, regulatory structures, including the likelihood of obtaining regulatory approval, and the anticipated profitability of such product. For clarity, the exertion of Commercially Reasonable
Efforts will not require that a party actually accomplish the applicable objectives or tasks. 
 1.3 Confidential Information means all technical
information, inventions, developments, discoveries, software, know-how, methods, techniques, formulae, data, processes, and other proprietary ideas, whether or not patentable, that a disclosing party
identifies as confidential or proprietary at the time it is delivered or communicated to a receiving party or its Affiliates or sublicensees. 
 1.4
Consulting Agreement means that certain Consulting Agreement entered into as of October 24, 2014 by and between Dr. Adrian Krainer and ASOthera, attached as Exhibit E. 

1.5 Event of Force Majeure means an unforeseeable act that wholly prevents a party from performing one or more of its material duties under the
Agreement and that was outside of the reasonable control of the party. An Event of Force Majeure includes acts of war or of nature, insurrection and riot, labor strikes, and delays imposed by regulatory agencies. 

1.6 Field means all applications. 
 1.7
Improvements means inventions that are conceived or reduced to practice solely or jointly by Dr. Adrian Krainer during the Patent Period and that are dominated by (A) any patent claims directed to Patent Period Inventions or
(B) any patent claims of the patent applications and patents included in Exhibit A. 
 1.8 Licensed
Know-how means know-how and information developed by Dr. Adrian Krainer or others in Dr. Krainer’s laboratory that is necessary for practicing the
Licensed Patent Rights and that CSHL has the right to license, including any such unpatented inventions, formulas, methods, plans, processes, specifications, characteristics, designs, know-how, experience, and
trade secrets. 
 1.9 Licensed Patent Rights means CSHL’s interest in (A) the patent applications and patents listed in Exhibit A,
(B) any patent applications claiming or covering any Patent Period Inventions, and (C) any patent applications claiming or covering Improvements; and in each case, any divisionals, continuations, continuations-in-part, and all patents issuing therefrom, and any and all extensions, reexaminations, reissues and corresponding foreign patent rights. 

  

					
		  		  	
		  	2	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 1.10 Licensed Products means any product for use in the Field that if made, used, sold, offered for
sale or imported absent the license granted hereunder would infringe a Valid Claim, or that uses or incorporates the Licensed Know-how. 

1.11 Net Sales means the total amount invoiced for each Sale by ASOthera or its Affiliates, sublicensees or sublicensees’ Affiliates, less
Qualifying Costs directly attributable to a Sale and actually included in the invoiced amount and borne by ASOthera or its Affiliates, sublicensees or sublicensees’ Affiliates. Where a Licensed Product is sold as part of a group of products or
services, the net sales of such group will be allocated to the Licensed Product in a consistent and equitable manner that reflects the contribution of the Licensed Product to the amounts invoiced for such group; provided, however, that in no event
will the Net Sales for such Licensed Product be less than the fair market value, where for this purpose, the words “fair market value” means the cash consideration that ASOthera or its Affiliates, sublicensees or sublicensees’
Affiliates would realize from an unrelated buyer in an arms’ length sale of an identical item sold in the same quantity and at the time and place of the transaction. 

1.12 Patent Period means the period commencing on October 24, 2014 and continuing until (A) expiration or termination of the Sponsored
Research Agreement or (B) expiration or termination of the Consulting Agreement, whichever occurs later. 
 1.13 Patent Period Inventions means
any inventions that are conceived or reduced to practice solely or jointly by Dr. Adrian Krainer during the Patent Period in connection with conduct of the Sponsored Research (as defined in the Sponsored Research Agreement) or performance of
consulting services pursuant to the Consulting Agreement. 
 1.14 Phase 1 Trial means a human clinical trial that is intended to initially evaluate
the safety and/or pharmacological effect of a Licensed Product in subjects or that would otherwise satisfy requirements of 21 C.F.R. 312.21(a), or its foreign equivalent. 

1.15 Phase 3 Trial means a human clinical trial in any country, the results of which could be used to establish safety and efficacy of a Licensed
Product as a basis for an NDA or would otherwise satisfy requirements of 21 CFR 312.21(c), or its foreign equivalent. 
 1.16 Qualifying
Costs means: (1) customary discounts in the trade for quantity purchased, prompt payment or wholesalers, distributors, government authorities, benefit management organizations, health insurance carriers, hospitals, group purchasing
organizations and other institutions; (2) credits or refunds for price adjustments, claims or returns that do not exceed the original invoice amount; (3) prepaid outbound transportation expenses and transportation insurance premiums and
other distribution handling charges; and (4) any sales, use, excise turnover, inventory, value-added or similar taxes, custom or other duties and compulsory payments to governmental authorities and any other governmental charges imposed upon
the production, importation, delivery, use or sale of such Licensed Product to Third Parties. 

  

					
		  		  	
		  	3	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 1.17 Royalty Term means the period commending on the Effective Date and ending upon the expiration of
the last to expire of the Licensed Patent Rights or expiration of marketing exclusivity granted by a regulatory authority, whichever occurs later. 
 1.18
Sale means any bona fide transaction with a Third Party for which consideration is received or expected for the sale, use, lease, transfer or other disposition of a Licensed Product made following the receipt of final marketing approval from
the applicable health regulatory authorities in the country of sale, and a Sale is deemed completed at the time that ASOthera, or its Affiliate, sublicensee or sublicensee’s Affiliate invoices, ships or receives payment for a Licensed Product,
whichever occurs first. For the avoidance of doubt, the sale, use, lease, transfer or other disposition of Licensed Products between or among ASOthera, its Affiliates, its sublicensees or its sublicensees’ Affiliates for the purpose of resale
to a Third Party will not be considered a Sale under this Agreement. 
 1.19 Sponsored Research Agreement means the Sponsored Research Agreement
entered into as of October 24, 2014 by and between CSHL and ASOthera, and amended as of April 30, 2015 and July 31, 2015. 
 1.20
Sublicense means any right granted, license given or agreement entered into, by ASOthera to or with any other person or entity, under or with respect to or permitting any use of any of the Licensed Patent Rights or otherwise permitting the
development, manufacture, marketing, distribution and/or sale of Licensed Products (regardless of whether such grant of rights, license given or agreement entered into is referred to or is described as a sublicense).    For
clarity, “Sublicense” does not include: 
 (A) a grant by ASOthera as part of a Sale of a Licensed Product to a Third Party of the
implied license (1) to use such Licensed Product or (2) to resell such Licensed Product, provided that the only consideration (whether monetary or non-monetary) received by ASOthera, or any Affiliate
of ASOthera, in connection with such grant is the fair market value of the Licensed Product sold; or 
 (B) any agreement in which ASOthera
grants its Affiliate the right to perform or exercise some or all of ASOthera’s rights and/or obligations under the License Agreement, as long as such Affiliate does not pay ASOthera any consideration (in any form) actually for such grant. 

1.21 Sublicense Revenue means all compensation or consideration of any kind received pursuant to a Sublicense, other than royalties, and includes any
payments made by a Third Party to ASOthera on behalf of a sublicensee; provided, however, that Sublicense Revenue specifically excludes: 

(A) any royalties or profit share amounts attributable to sales of Licensed Products (provided that such sales form the basis of royalties paid
to CSHL); 
 (B) payments specifically committed in the Sublicense to cover actual costs incurred or to be incurred by ASOthera (including
equipment purchases and full-time equivalent personnel actually provided by ASOthera) in the research and development of Licensed Products which are the subject matter of the Sublicense; 

  

					
		  		  	
		  	4	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 (C) reimbursement of payments paid by ASOthera to CSHL for milestone events or amounts
incurred with respect to the filing, prosecution or maintenance of any Licensed Patent Rights; 
 (D) loans or other debt obligations (any
amounts which are forgiven will be deemed Sublicense Revenue); 
 (E) amounts received from any Third Party for the purchase of equity at
fair market value; 
 (F) securities of an Affiliate received from an Affiliate that are not provided in exchange for the grant of a
Sublicense; and 
 (G) amounts received in consideration of the sale of substantially all of the business or assets of ASOthera or any of its
Affiliates. 
 1.22 Third Party means any person or entity other than CSHL and ASOthera and its Affiliates, sublicensees and sublicensees’
Affiliates. For the avoidance of doubt, when the term “third party” is used in this Agreement without capitalization it means any person or entity other than CSHL and ASOthera. 

1.23 Valid Claim means (A) a claim of an issued and unexpired patent included within the Licensed Patent Rights, which has not been held
permanently revoked, unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction in an unappealed or unappealable decision, and which has not been admitted to be invalid or unenforceable through reissue
or disclaimer or otherwise or (B) a claim of a pending patent application included within the Licensed Patent Rights that has not been withdrawn, canceled, or disclaimed or has not been pending for more than five years. 

2. LICENSE 
 2.1 License Grant. CSHL hereby grants
ASOthera: 
 (A) an exclusive, worldwide, royalty-bearing, sublicensable (through multiple tiers, subject to the conditions of
Section 2.4) license under the Licensed Patent Rights, and 
 (B) a
non-exclusive, worldwide, royalty-free license under the Licensed Know-how, 

in each case to research, develop, manufacture, make, have made, use, offer for sale, sell, import and commercialize Licensed Products in the
Field. 

  

					
		  		  	
		  	5	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 The foregoing license grants are referred to herein collectively as the “Licenses.” 

2.2 Reservation of Rights by CSHL. Notwithstanding the Licenses granted to ASOthera pursuant to Section 2.1 hereof, CSHL
reserves the worldwide right to practice, and to permit other non-profit non-commercial entities to practice (under a specific written agreement with CSHL or upon
written notification to ASOthera), the Licensed Patent Rights and Licensed Know-how for all non-profit non-commercial educational
and research purposes and without any payment therefor, and provided that any materials 
 provided to any third party
non-profit non-commercial entity will be furnished pursuant to industry standard confidentiality and material transfer agreements that comply with this Agreement. 

2.3 U.S. Government Rights. The parties acknowledge that the United States government retains rights in intellectual property funded under any grant or
similar contract with a Federal agency. The Licenses granted to ASOthera hereunder are expressly subject to all applicable rights of the United States government, including, where applicable, those reserved under Public Laws 96-517, 97-256 and 98-260, codified at 35 U.S.C. 200-212, and any regulations issued
thereunder. 
 2.4 Sublicense Conditions. ASOthera’s right to grant Sublicenses under the Licenses is subject to each of the following
conditions: 
 (A) In each Sublicense agreement, ASOthera will require the sublicensee to comply with the terms and conditions of this
Agreement. 
 (B) Within thirty (30) days after ASOthera enters into a Sublicense agreement, ASOthera will deliver to CSHL an accurate
copy of the Sublicense agreement written in the English language; provided, however, that any copy of a Sublicense agreement may be reasonably redacted to exclude confidential information of the sublicensee that is not necessary for assessing
ASOthera’s compliance with this section. CSHL’s receipt of the Sublicense agreement, however, will constitute neither an approval of the Sublicense nor a waiver of any right of CSHL or obligation of ASOthera under this Agreement. 

(C) ASOthera’s execution of a Sublicense agreement will not relieve ASOthera of any of its obligations under this Agreement. ASOthera is
primarily liable to CSHL for any act or omission of an Affiliate, sublicensee or Affiliate of a sublicensee of ASOthera that would be a breach of this Agreement if performed or omitted by ASOthera, and ASOthera will be deemed to be in breach of this
Agreement as a result of such act or omission. 

  

					
		  		  	
		  	6	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 3. DILIGENCE 

3.1 Development Plans and Progress Reports. Within sixty (60) days after the Effective Date, and annually thereafter throughout the Term, ASOthera
will submit to CSHL a written development plan and progress report documenting the technical and relevant business development of Licensed Products in order to demonstrate ASOthera’s capability to bring Licensed Products covered by the Licensed
Patent Rights and Licensed Know-how to commercialization. 
 3.2 Diligence Plan. ASOthera intends to build a
pharmaceutical company with a drug discovery pipeline based on antisense oligonucleotides that utilize certain CSHL technologies, including technology known at CSHL by the acronym TANGO. ASOthera will use Commercially Reasonable Efforts to
raise at least $[*] in equity investment from reputable institutional investors, and to design antisense oligonucleotides based on the TANGO technology. If hit oligonucleotides are identified, ASOthera will use Commercially Reasonable Efforts to
perform lead optimization to improve the following properties: 1) [*], 2) [*], 3) [*], 4) [*], and 5) [*]. If, in ASOthera’s sole discretion, at least one oligonucleotide satisfies the criteria in clauses 1) – 5), then ASOthera will
use Commercially Reasonable Efforts to perform pre-clinical activities to identify at least one oligonucleotide that possesses suitable in vitro and in vivo efficacies, PK and safety properties
for clinical development, and at least one IND filing will be submitted to the FDA, or one or more similar international regulatory authorities, for approval of initial Phase 1 or Phase 1/2 human clinical trials. 

3.3 Diligence Milestones. ASOthera will use Commercially Reasonable Efforts to achieve each milestone specified below (each, a “Diligence
Milestone”) for at least one Licensed Product: 
 (A) [*]; 

(B) [*]; 
 (C) [*]; 

(D) [*]; 
 (E) [*]. 

3.4 Failure to Achieve a Diligence Milestone. If ASOthera believes it will be unable to achieve a Diligence Milestone, then ASOthera will notify CSHL.
If such Diligence Milestone has an agreed date, then ASOthera will notify CSHL no later than [*] before the target date for fulfillment of such Diligence Milestone. 

(A) If ASOthera has been using Commercially Reasonable Efforts (as demonstrated by reasonable supporting documentation) to achieve such
Diligence Milestone, CSHL will grant ASOthera a [*] extension of any such Diligence Milestone. 
 (B) At the end of such extension, if such
Diligence Milestone has not been achieved and ASOthera has been using Commercially Reasonable Efforts (as demonstrated by reasonable supporting documentation) to achieve such Diligence Milestone, ASOthera will present a revised development plan
outlining its plan to 

  

					
		  		  	
		  	7	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 
achieve such Diligence Milestone. If such plan is acceptable to CSHL, such acceptance not to be unreasonably withheld, CSHL agrees that the date to achieve a given Diligence Milestone can be
extended for an additional [*] provided ASOthera pays an extension fee of $[*] (“Extension Fee”). 
 (C) The non-achievement of a Diligence Milestone after a [*] extension period allowed by payment of such an Extension Fee may constitute a breach of the Agreement. It will not be a breach of the Agreement, and CSHL may not
withhold its consent to any extension, where the failure to do so is as a result of the occurrence of an Event of Force Majeure during the Term. 

(D) It is understood and agreed that the foregoing obligations may be satisfied by ASOthera directly, or by its sublicensees. 

4. FEES AND ROYALTIES 
 4.1 Equity Issuance.
ASOthera will issue to CSHL on the Effective Date such number of shares of the common stock of ASOthera, par value $0.0001 per share (the “Common Stock”) as will cause CSHL to own five percent (5%) of the capital stock of ASOthera on a
fully diluted basis, assuming the exercise, conversion and exchange of all outstanding securities of ASOthera for or into shares of Common Stock. The issuance of such shares of Common Stock to CSHL will be pursuant to a Stock Purchase Agreement
substantially in the form attached hereto as Exhibit B and will be subject to customary transfer restrictions comparable to the founders of ASOthera. 

4.2 Dilution Protection. Through the closing in a single transaction or in a series of related transactions of the sale of capital stock of ASOthera
for an aggregate gross purchase price paid to ASOthera of no less than $5 Million (including, without limitation, the conversion of the principal amount of and accrued interest and any other amounts owing on the promissory notes issued to Apple Tree
Partners IV, L.P. (“Apple Tree”) pursuant to that certain Note Purchase Agreement by and among ASOthera and Apple Tree dated November 13, 2014 and that certain Note Purchase Agreement by and among ASOthera and Apple Tree dated
June 12, 2015), ASOthera will issue to CSHL, from time to time and at no additional consideration, such additional shares of Common Stock as will cause CSHL to continue to hold in the aggregate five percent (5%) of the capital stock of ASOthera
on a fully diluted basis, assuming the exercise, conversion and exchange of all outstanding securities of ASOthera for or into shares of Common Stock. At the closing of such equity financing, CSHL agrees to enter into financing agreements in a form
substantially similar to the form agreements set forth as Model Legal Documents on http://www.nvca.org. No additional anti-dilution protection will apply to the CSHL shares for any amounts raised by ASOthera in excess of $5 Million. 

  

					
		  		  	
		  	8	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 4.3 Board Seat. For so long as CSHL owns at least two and one half percent (2.5%) of the fully diluted
capital of ASOthera, CSHL will have the right to: 
 (A) designate one representative to attend all meetings of ASOthera’s Board of
Directors (the “Board”) in a non-voting observer capacity (such representative, an “Observer”); provided, however, that (1) as a condition precedent to the rights provided for
under this Section 4.3(A), each Observer and any other CSHL employee having access to any of the information provided by ASOthera to the Board agrees to hold in confidence and trust all such information received during such
Board meetings or otherwise, and (2) ASOthera may not provide information to any Observer or may exclude any Observer from any Board meeting or portion thereof if delivery of such information or attendance at such Board meeting or portion
thereof would result in disclosure of trade secrets to such Observer or would adversely affect the attorney-client privilege between ASOthera and its counsel; and 

(B) approve the appointment of any independent director to the Board, such approval not to be unreasonably withheld or delayed. 

4.4 License Maintenance Fees. ASOthera will pay to CSHL [*], either in cash or in equivalent value of ASOthera Common Stock, beginning on the [*]
anniversary of the Effective Date and each year thereafter during the Term. Each annual license maintenance fee will be due within [*] business days of the anniversary of the Effective Date and is nonrefundable; however, the license maintenance fee
will be fully creditable against any royalties or milestone payments under this Agreement that accrue in the following four Quarters. The term “Quarter” means each three-month period beginning on January 1, April 1, July 1
and October 1. ASOthera will have the sole right to determine if any such annual maintenance fee will be paid to CSHL in cash or in ASOthera Common Stock. 

4.5 Milestone Payments. ASOthera will pay to CSHL the applicable milestone payment listed in the table below for achievement of a milestone event by
the first Licensed Product that if made, used, sold, offered for sale or imported absent the License granted hereunder would infringe a Valid Claim of the Licensed Patent Rights: 

 

			
	 Milestone Event
	  	Milestone Payment For First Licensed
Product to Achieve the Milestone Event
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]

 In no event will a milestone payment be paid more than once, even if one or more additional Licensed Products subsequently
achieve the same milestone event. 
 CSHL will have the right to propose that any of such milestone payments (or any portion thereof) be paid to CSHL in
ASOthera Common Stock and ASOthera will have the sole right to determine whether or not to agree to such request. 

  

					
		  		  	
		  	9	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 4.6 Earned Royalties. During the Royalty Term, ASOthera will pay CSHL the following royalties: 

(A) [*] on Net Sales of Licensed Products whose composition of matter falls within one or more Valid Claims of the Licensed Patent Rights; and

 (B) [*] on Net Sales of Licensed Products whose composition of matter does not fall within one or more Valid Claims of the Licensed Patent
Rights but (1) that otherwise fall within one or more Valid Claims of the Licensed Patent Rights, or (2) that previously fell within one or more Valid Claims of the Licensed Patent Rights and are sold or offered for sale during a period of
market exclusivity granted by a regulatory authority to ASOthera (or any of its Affiliates, sublicensees or sublicensees’ Affiliates) with regard to such Licensed Product. 

Except as otherwise set forth in Subsection 4.6 (B)(2) above, no royalty will be due on Net Sales of Licensed Products whose manufacture, use, sale,
offer for sale or importation does not infringe a Valid Claim. 
 Only one royalty will be owed for a Licensed Product regardless of how many Valid Claims
cover such Product. 
 4.7 Exclusion from Royalties. No royalty will be due with respect to commercially reasonable quantities of units of Licensed
Products used solely for clinical trials, other internal research or development purposes, in a compassionate use program, or as samples or promotional goods. 

4.8 Stacking Protection. ASOthera may offset an amount equal to [*] of any third-party royalty payments owed with respect to sale of a Licensed Product
against the royalty payments that are due to CSHL for such Licensed Product; provided that in no event, will the royalty payments to CSHL be reduced by more than [*] of the amount otherwise due to CSHL with respect to such Licensed Product (i.e., no
less than [*] and [*], respectively). 
 4.9 Sublicense Revenue Sharing. For each Sublicense granted by ASOthera, ASOthera will pay to CSHL 20% of
all Sublicense Revenue. For the avoidance of doubt, Net Sales of any Licensed Product by any sublicensee or sublicensee’s Affiliate are subject to ASOthera’s royalty obligation to CSHL. 

The percentage of Sublicense Revenue payable to CSHL will be reduced to [*]. 

4.10 Allocation Method. Notwithstanding Section 4.9, if a Sublicense is part of a transaction in which ASOthera also conveys
rights to technology or intellectual property other than the Licensed Patent Rights or the Licensed Know-how that is reasonably necessary for, or directed to, the discovery, development, manufacture, sale or
importation of a Licensed Product, then ASOthera will propose in good faith by written notice to CSHL a basis for allocation of the consideration received by ASOthera and its Affiliates for such transaction between the Licensed Patent Rights and
such other 

  

					
		  		  	
		  	10	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 
technology and intellectual property based on the relative value to be attributed to the Sublicense as part of the overall transaction. In the event CSHL does not agree with ASOthera’s
calculation of the relative value to be attributed to the Sublicense, CSHL will notify ASOthera thereof and the parties will resolve such disagreement in accordance with the dispute resolution procedures set forth in
Section 13.9. 
 The amount payable to CSHL with respect to sublicense fees received in connection with such transaction will be
determined by the following equation: 
 [*] 

5. REPORTS AND PAYMENTS 
 5.1 Royalty Reports.
Within [*] after the end of each Quarter following first commercial Sale of a Licensed Product, ASOthera will deliver to CSHL a report, certified by the chief financial officer of ASOthera, detailing the calculation of all royalties and fees due to
CSHL for such Quarter. The report will include, at a minimum: 
 (A) [*]; 

(B) [*]; 
 (C) [*]; 

(D) [*]; 
 (E) [*]; and 

(F) [*]. 
 5.2 Payments. All amounts paid
by ASOthera to CSHL under this Agreement will be non-refundable. ASOthera will pay all royalties and fees due to CSHL under Sections 4.5, 4.6 and 4.9 within [*] after the end of the Quarter in which the
royalties or fees accrue. Any income, remittance, or other taxes on such royalties required to be withheld at the source will be the exclusive responsibility of ASOthera, and will not be used to decrease the amount of royalties due to CSHL
hereunder. 
 5.3 Records. ASOthera will maintain, and will cause its Affiliates and sublicensees to maintain, complete and accurate books and
records to verify Sales, Net Sales, and all of the royalties, fees, and other payments payable under this Agreement. The records for each Quarter will be maintained for at least [*] after submission of the applicable report required under
Section 5.1. 

  

					
		  		  	
		  	11	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 5.4 Audit Rights. Upon reasonable prior written notice to ASOthera, ASOthera and its Affiliates and
sublicensees will provide CSHL and, subject to reasonable obligations of confidentiality, its accountants with access to all of the books and records required by Section 5.3 to conduct a review or audit of Sales, Net Sales,
and all of the royalties, fees, and other payments payable under this Agreement. Access will be made available: 
 (A) during normal business
hours; 
 (B) in a manner reasonably designed to facilitate CSHL’s review or audit without unreasonable disruption to ASOthera’s
business; and 
 (C) no more than once each calendar year during the Term and for a period of [*] thereafter. The review or audit may cover a
period of not more than [*] before the first day of the Quarter in which the review or audit is requested. 
 ASOthera will promptly pay to CSHL the amount
of any underpayment determined by the review or audit plus accrued interest. If the review or audit determines that ASOthera has underpaid any royalty payment by [*] or more, then ASOthera will also promptly pay the costs and expenses of CSHL and
its accountants in connection with the review or audit. 
 5.5 Currency. All dollar amounts referred to in this Agreement are expressed in United
States dollars. All payments will be made in United States dollars. If ASOthera receives payment from a third party in a currency other than United States dollars for which a royalty or fee is owed under this Agreement, then: 

(A) the payment will be converted into United States dollars at the conversion rate for the foreign currency as published in the eastern
edition of the Wall Street Journal as of the last business day of the Quarter in which the payment was received by ASOthera, and 
 (B) the
conversion computation will be documented by ASOthera in the applicable report delivered to CSHL under Section 5.1. 
 5.6
Place of Payment. All payments by ASOthera are payable to Cold Spring Harbor Laboratory and will be made to the following addresses: 
  

			
	 By Electronic Transfer:
	  	 By Check:

	[*]	  	Cold Spring Harbor Laboratory
		  	One Bungtown Road
		  	Cold Spring Harbor, NY 11724
		  	Attn: Office of Technology Transfer

 5.7 Interest. All amounts that are not paid by ASOthera when due will accrue interest from the date due until paid at a
rate equal to the U.S. prime rate plus [*] as published by the Wall Street Journal on the last day of the applicable period (or the maximum allowed by law, if less). 

  

					
		  		  	
		  	12	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 6. CONFIDENTIALITY 

6.1 ASOthera’s Confidentiality Obligation. ASOthera will maintain in confidence and not disclose to any Third Party any CSHL Confidential
Information. ASOthera will use the CSHL Confidential Information only for the purposes of performing its obligations and exercising its rights under this Agreement. ASOthera will ensure that ASOthera’s employees and its Affiliates and
sublicensees have access to CSHL Confidential Information only on a need to know basis and are obligated in writing to abide by ASOthera’s obligations under this Article 6. 

6.2 CSHL’s Confidentiality Obligation. CSHL will maintain in confidence and not disclose to any third party any ASOthera Confidential
Information. CSHL will use the ASOthera Confidential Information only for the purposes of performing its obligations and exercising its rights under this Agreement. CSHL will ensure that CSHL’s employees have access to ASOthera Confidential
Information only on a need to know basis and are obligated in writing to abide by CSHL’s obligations under this Article 6. 
 6.3
Exceptions. The obligations under Sections 6.1 and 6.2 will not apply to: 
 (A) information that is known to the receiving
party prior to the time of disclosure, to the extent evidenced by written records; 
 (B) information that is disclosed to the receiving
party by a third party that has the right to make such disclosure; 
 (C) information that is independently developed by the receiving party
without use of the Confidential Information, to the extent evidenced by written records; 
 (D) information that becomes patented, published
or otherwise part of the public domain through no fault of the receiving party; or 
 (E) information that is required to be disclosed by
order of United States governmental authority or a court of competent jurisdiction, provided that the receiving party must use its best efforts to obtain confidential treatment of such information by such agency or court. 

7. TERM AND TERMINATION 
 7.1 Term. The term of
this Agreement will begin on the Effective Date and, unless terminated earlier, will continue in full force and effect on a Licensed Product-by-Licensed Product and country-by-country basis until the expiration of the last-to-expire Valid Claim covering the
making, using, selling, offering to sell or importing of such Licensed Product in such country or until the expiration of market exclusivity granted by a regulatory authority in such country, whichever occurs later (“Term”). Unless the
Agreement is terminated by either party pursuant to Sections 7.2 or 7.3 hereof , ASOthera will have a perpetual royalty-free non-exclusive license under the Licensed
Know-how following expiration of the Term. 

  

					
		  		  	
		  	13	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 7.2 Termination by CSHL. CSHL may terminate this Agreement effective upon written notice to ASOthera
if: 
 (A) ASOthera materially breaches this Agreement and does not cure such breach within ninety (90) days after written notice of
such breach; notwithstanding the foregoing, in the event of a good faith dispute with respect to the existence of a material breach, the applicable cure period will be tolled until such time as the dispute is finally resolved in accordance with the
dispute resolution mechanism specified in Sections 13.8 and 13.9; 
 (B) ASOthera, or any of its Affiliates, sublicensees or
sublicensees’ Affiliates, challenges the validity or enforceability of any Valid Claim, unless such challenge is withdrawn within thirty (30) days after receipt of a notice from CSHL under this section; provided, however, that this section
will not be applicable with respect to any such challenge by a sublicensee or sublicensees’ Affiliate if ASOthera terminates the applicable Sublicense within thirty (30) days after receipt of a notice from CSHL under this section; or 

(C) ASOthera commits any act of bankruptcy, becomes insolvent, is unable to pay its debts as they become due, files a petition under any
bankruptcy or insolvency act or has any such petition filed against it which is not dismissed within sixty (60) days. 
 7.3 Termination by
ASOthera. Notwithstanding anything contained herein to the contrary, ASOthera has the right to terminate this Agreement at any time in its sole discretion by giving ninety (90) days advance written notice to CSHL. 

7.4 Effect of Termination. If this Agreement is terminated for any reason (excluding, for the avoidance of doubt, expiration of the Term under
Section 7.1): 
 (A) the Licenses terminate; 

(B) ASOthera and all its Affiliates and sublicensees will cease making, having made, using, importing, selling and offering for sale all
Licensed Products; 
 (C) ASOthera will pay to CSHL all amounts owed to CSHL through the date of termination of this Agreement within ninety
(90) days of such date of termination; 
 (D) in the case of termination under Section 7.2, all duties of CSHL
and all rights (but not all duties) of ASOthera under this Agreement will immediately terminate without further action required by either CSHL or ASOthera; 

(E) each party will, at the other party’s request, return to such other party all Confidential Information of such other party; and 

  

					
		  		  	
		  	14	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 (F) any Sublicense granted prior to such termination will survive as a direct license with
CSHL and the sublicensee will automatically become a direct licensee of CSHL with respect to the rights originally sublicensed to the sublicensee; provided that: (i) such sublicensee is not in breach of its Sublicense; (ii) such sublicensee
agrees to comply with all of the terms of this Agreement to the extent applicable to the rights originally sublicensed to such sublicensee; and (iii) such sublicensee agrees to pay directly to CSHL such sublicensee’s payments under this
Agreement to the extent applicable to the rights sublicensed to such sublicensee. ASOthera agrees that it will confirm the foregoing in writing at the request and for the benefit of CSHL and/or the sublicensee. 

7.5 Surviving Rights and Obligations. Termination of this Agreement will not affect the rights and obligations of the parties accrued prior to
termination hereof. The provisions of Articles 4, 5, 6, 9 and 11 and Sections 7.4, 10.3, and 13.6 will survive the termination of this Agreement for any reason in accordance with their respective terms. 

8. PATENT MAINTENANCE AND REIMBURSEMENT 
 8.1 Patent
Maintenance. CSHL controls the preparation, prosecution and maintenance of 
 the Licensed Patent Rights and the selection of patent counsel, with input
from ASOthera. If, however, ASOthera desires to manage the preparation, prosecution and maintenance of the Licensed Patent Rights with input from CSHL, then ASOthera and CSHL will enter into a Client and Billing Agreement with patent counsel in the
form attached as Exhibit C. 
 8.2 Patent Reimbursement. Within [*] days after the Effective Date, ASOthera will reimburse CSHL for all
historically accrued, un-reimbursed attorneys’ fees, expenses, official fees and all other charges accumulated prior to the Effective Date incident to the preparation, prosecution and maintenance of the
Licensed Patent Rights. ASOthera will reimburse CSHL for all documented attorneys’ fees, expenses, official fees and all other charges incident to the preparation, prosecution and maintenance of the Licensed Patent Rights within [*] after
ASOthera’s receipt of invoices for such fees, expenses, and charges unless agreed otherwise in a Client and Billing Agreement. 
 9.
INFRINGEMENT 
 9.1 Notice. ASOthera and CSHL will notify each other promptly of any infringement of the Licensed Patent Rights that may come
to their attention. ASOthera and CSHL will consult each other in a timely manner concerning any appropriate response to the infringement. 
 9.2 ASOthera
Prosecution. ASOthera may prosecute an action against a Third Party to protect the Licensed Patent Rights, including an infringement action. The expenses of such action, including attorneys’ fees, expert fees and all other costs and
expenses of the litigation, including appeals, settlement processes and alternative dispute mechanisms, will be borne by ASOthera. 

  

					
		  		  	
		  	15	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 CSHL will execute all necessary and proper documents and take all other appropriate actions to allow ASOthera
to institute and prosecute the action. 
 Any award paid by a Third Party as a result of such action (whether by way of settlement or otherwise) will first
be applied toward reimbursement of attorneys’ fees, expert fees and all other costs and expenses of the litigation, including appeals, settlement processes and alternative dispute mechanisms, and the excess, if any, will be retained by
ASOthera, except that the same will be deemed to constitute Sublicense Revenue under Sections 4.9 and 4.10, as if the Sublicense there referenced had been executed on the date of final resolution (by entry of judgment or settlement) of such
action. Notwithstanding the foregoing, it is understood and agreed between the parties that reduction of the percentage of Sublicense Revenue payable to CSHL pursuant to Subsections 4.9(A) or 4.9(B) will not apply to payments made pursuant to
this section. 
 9.3     CSHL Prosecution. If ASOthera, without CSHL’s consent (not to be unreasonably withheld), does not
institute such action against a Third Party, CSHL will have the right but not the obligation to institute an action. Such consent of CSHL may not be withheld where ASOthera provides a reasonable enforcement strategy which involves pursuing other
infringers first. If CSHL elects to prosecute such action, then financial recoveries will be retained by CSHL in their entirety. 
 9.4
    Cooperation. In any litigation under this Article 9, either party, at the request and expense of the other party, will cooperate to the fullest extent reasonably possible. This
Section 9.4 will not be construed to require either party to undertake any activities, including legal discovery, at the request of any Third Party, except as may be required by lawful process of a court of competent
jurisdiction. 
 10. REPRESENTAIONS; DISCLAIMER; LIMITATION OF LIABILITIES 

10.1 CSHL Representation. CSHL hereby represents to ASOthera that: 

(A) it is an educational corporation duly organized, validly existing and in good standing under the laws of New York; 

(B) it has all requisite corporate power, right and authority to enter into and perform its obligations under this Agreement; 

(C) this Agreement constitutes its valid and binding obligation enforceable in accordance with its terms; and 

(D) to CSHL’s knowledge as of the Effective Date, there are no inventions that have been conceived or reduced to practice solely or
jointly by Dr. Adrian Krainer prior to the Effective Date that are dominated by or dominate any patent claims of provisional patent application number [*]. 

  

					
		  		  	
		  	16	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 10.2 ASOthera Representation. ASOthera hereby represents to CSHL that: 

(A) it is a corporation duly organized, validly existing and in good standing under the laws of Delaware; 

(B) it has all requisite corporate power, right and authority to enter into and perform its obligations under this Agreement; 

(C) the capitalization table attached hereto as Exhibit D accurately reflects all of the issued and outstanding shares of stock,
options, warrants and other securities of ASOthera as of the Effective Date; 
 (D) this Agreement constitutes its valid and binding
obligation enforceable in accordance with its terms; 
 (E) its execution and delivery of this Agreement, and compliance with the terms
hereof, do not and will not conflict with or result in a breach of any terms of, or constitute a default under, any agreement, obligation or instrument to which it is a party or by which it is bound. 

10.3 Disclaimer. The Licensed Patent Rights and Licensed Know-how are provided on an “as is”
basis. Except as explicitly set forth in Section 10.1(D), CSHL makes no representations or warranties, express or implied, including but not limited to any warranty of accuracy, completeness,
performance, merchantability, fitness for a particular purpose, commercial utility or noninfringement. CSHL will not be liable to ASOthera, its Affiliates, sublicensees or sublicensees’ Affiliates, or the successors or assigns of any of them,
or any Third Party with respect to any claim: arising from use of the Licensed Patent Rights or Licensed Know-how; or arising from the development, testing, manufacture, use or sale of Licensed Products.
Except with respect to breach of Section 6 (Confidentiality), in no event will either party be liable to the other party, or its Affiliates, sublicensees, or sublicensees’ Affiliates, or any
Third Party, for any consequential, incidental, special or indirect damages (including, but not limited to, any lost profits or business interruption) based on activity arising out of or related to this Agreement, whether pursuant to a claim of
breach of contract or any other claim of any type.  
 10.4 Assumption of Risk. As between ASOthera (and its Affiliates, sublicensees and
sublicensees’ Affiliates) and CSHL, ASOthera and its Affiliates, sublicensees and sublicensees’ Affiliates hereby assume the entire risk as to the performance, safety and efficacy of any Licensed Product. 

  

					
		  		  	
		  	17	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 11. INDEMNIFICATION 

11.1 Indemnification. ASOthera will defend, indemnify, and hold harmless CSHL, and its trustees, officers, faculty, agents, employees and students
(each, an “Indemnified Party”) from and against any and all liability, loss, damage, action, claim, or expense suffered or incurred by the Indemnified Parties, including attorneys’ fees and expenses (collectively,
“Liabilities”), arising out of or resulting from: 
 (A) any third party claim arising out of or resulting from the
development, testing, use, manufacture, promotion, sale or other disposition of any Licensed Patent Rights, Licensed Know-how or Licensed Products by ASOthera, its Affiliates, sublicensees, sublicensees’
Affiliates, assignees or vendors or associated Third Parties; 
 (B) any third party claim arising out of or resulting from any material
breach of this Agreement by ASOthera or its Affiliates, sublicensees or sublicensees’ Affiliates; and 
 (C) the enforcement of this
Article 11 by any Indemnified Party. 
 Liabilities include, but are not limited to: (1) any product liability or other claim of any kind
related to use by a third party of a Licensed Product that was manufactured, sold or otherwise disposed of by ASOthera, or its Affiliates, sublicensees, sublicensees’ Affiliates, assignees, vendors or Third Parties; (2) a claim by a third
party that the Licensed Patent Rights, Licensed Know-how or the design, composition, manufacture, use, sale or other disposition of any Licensed Product infringes or violates any patent, copyright, trade
secret, trademark or other intellectual property right of such third party (provided that the foregoing will not include any challenge to the validity or enforceability of any Valid Claim by any of ASOthera’s sublicensees or such
sublicensees’ Affiliates); and (3) a claim by a third party arising out of or resulting from clinical trials or studies conducted by or on behalf of ASOthera, or its Affiliates, sublicensees, sublicensees’ Affiliates, assignees,
vendors or associated Third Parties relating to the Licensed Patent Rights, Licensed Know-how or the Licensed Products, such as claims by or on behalf of a human subject of any such trial or study. 

However, the foregoing will not apply to the extent any such Liabilities result or arise from the negligence, willful misconduct, or violation of applicable
law of any Indemnified Party, or from any breach by CSHL of its representations or warranties contained in this Agreement. 
 11.2 Other Provisions.
The obligation of ASOthera to indemnify, defend and hold harmless under this Article 11 will be contingent upon timely notification by CSHL to ASOthera of the claim or action; the tender by CSHL to ASOthera of full control over the conduct
and disposition of the claim or action; and reasonable cooperation by CSHL in the defense of the claim or action. ASOthera will not settle or compromise any claim or action giving rise to Liabilities in any manner that imposes any restrictions or
obligations on CSHL without CSHL’s prior written consent. If ASOthera fails or declines to assume the defense of any claim or action within forty-five (45) days after notice of the claim or action, then CSHL may assume the defense of such
claim or action for the account and at the risk of ASOthera, and any Liabilities related to such claim or action will be conclusively deemed a Liability of ASOthera. The indemnification rights of the Indemnified Parties under this Article 11
are in addition to all other rights that an Indemnified Party may have at law, in equity or otherwise. 

  

					
		  		  	
		  	18	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 12. INSURANCE 

12.1 Coverages. ASOthera will procure and maintain insurance policies for the following coverages with respect to personal injury, bodily injury and
property damage arising out of ASOthera’s performance under this Agreement: 
 (A) during the Term, comprehensive general liability,
including broad form and contractual liability, in a minimum amount of $2,000,000 combined single limit per occurrence and in the aggregate; 

(B) prior to the commencement of clinical trials involving Licensed Products, clinical trials coverage in a minimum amount of $5,000,000
combined single limit per occurrence and in the aggregate; and 
 (C) prior to the first commercial Sale of the first Licensed Product,
product liability coverage, in a minimum amount of $10,000,000 combined single limit per occurrence and in the aggregate. 
 CSHL may review periodically
the adequacy of the minimum amounts of insurance for each level of coverage required by this Section 12.1, and CSHL reserves the right to require ASOthera to adjust the limits accordingly. The required minimum amounts of
insurance do not constitute a limitation on ASOthera’s liability or indemnification obligations to CSHL under this Agreement. 
 12.2 Other
Requirements. The policies of insurance required by Section 12.1 will be issued by an insurance carrier with an A.M. Best rating of “A” or better and will name CSHL as an additional insured with respect to
ASOthera’s performance under this Agreement. ASOthera will provide CSHL with insurance certificates evidencing the required coverage within thirty (30) days after any request by CSHL therefor. Each certificate will provide that the
insurance carrier will notify CSHL in writing at least thirty (30) days prior to the cancellation or material change in coverage. 
 13. ADDITIONAL
PROVISIONS 
 13.1 Assignment. No rights hereunder may be assigned by either party, directly or by merger or other operation of law, without the
express written consent of the other party, which consent will not be unreasonably withheld or delayed; except that either party may, without such consent, assign this Agreement to any Affiliate or in connection with a merger, consolidation or
change of control of such party or a sale of all or substantially all of such party’s assets to which this Agreement relates. Any prohibited assignment of this Agreement or the rights hereunder will be null and void. No assignment will relieve
the assigning party of responsibility for the performance of any accrued obligations which it has prior to such assignment. Subject to the foregoing, this Agreement will be binding upon and will inure to the benefit of the parties and their
permitted assigns. 

  

					
		  		  	
		  	19	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 13.2 Waiver. A waiver by either party of a breach or violation of any provision of this Agreement will
not constitute or be construed as a waiver of any subsequent breach or violation of that provision or as a waiver of any breach or violation of any other provision of this Agreement. 

13.3 Independent Contractors. The parties are independent contractors. Nothing contained in this Agreement is intended to create an agency, partnership
or joint venture between the parties. At no time will either party make commitments or incur any charges or expenses for or on behalf of the other party. 

13.4 Capitalization Updates. ASOthera will promptly notify CSHL upon the close of each round of equity financing and will provide CSHL with an updated
capitalization table reflecting the closing of the equity financing series. Each such updated capitalization table will be incorporated into this Agreement. 

13.5 Compliance with Laws. ASOthera must comply with all prevailing laws, rules and regulations that apply to its activities or obligations under this
Agreement. For example, ASOthera will comply with applicable United States export laws and regulations. The transfer of certain technical data and commodities may require a license from the applicable agency of the United States government and/or
written assurances by ASOthera that ASOthera will not export data or commodities to certain foreign countries without prior approval of the agency. CSHL does not represent that no license is required, or that, if required, the license will issue.

 13.6 Use of Name. ASOthera and its Affiliates, sublicensees, sublicensees’ Affiliates, employees, and agents may not use the name, logo,
seal, trademark, or service mark (including any adaptation of them) of CSHL or any CSHL school, organization, trustee, officer, faculty member, employee, student or representative, without the prior written consent of CSHL. 

13.7 Notice. Notices under this Agreement will be in writing and sent by public courier and addressed as follows: 

If to CSHL: 
 Cold Spring Harbor
Laboratory 
 One Bungtown Road 

Cold Spring Harbor, New York 11724 

Attention: Office of Technology Transfer 

with a copy to: 
 Cold Spring
Harbor Laboratory 
 One Bungtown Road 

Cold Spring Harbor, New York 11724 

Attention: General Counsel 

  

					
		  		  	
		  	20	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 If to ASOthera: 

ASOthera Pharmaceuticals, Inc. 
 4
Washington Street 
 Lexington, MA 02421 

Attention: Huw Nash 
 With a copy
(which shall not constitute notice) to: 
 Fenwick & West 

1191 Second Avenue 
 10th Floor

 Seattle, WA 98101 

Attention: Effie Toshav, Esq. 
 13.8 Governing
Law; Jurisdiction. This Agreement will be governed by and construed in accordance with the laws of New York, without regard to principles relating to conflicts of law. Subject to Section 13.9, the courts of the State of
New York in New York County and the United States District Court for the Southern District of New York will have exclusive jurisdiction over the parties with respect to any dispute or controversy between them arising under or in connection with the
Agreement and, by execution and delivery of the Agreement, the parties to the Agreement (A) submit to the jurisdiction of those courts, including, but not limited to, the in personam and subject matter jurisdiction of those courts,
(B) waive any objection to such jurisdiction on the grounds of venue or forum non conveniens, the absence of in personam or subject matter jurisdiction and any similar grounds, (C) consent to service of process by mail or any other manner
permitted by law and (D) irrevocably agree to be bound by any such judgment rendered thereby in connection with the Agreement. These consents to jurisdiction will not be deemed to confer rights on any person other than the parties to the
Agreement. 
 13.9 Dispute Resolution. The parties understand and appreciate that their long-term mutual interest will be best served by a rapid and
fair resolution of any claims or disputes that may arise under this Agreement or from any dispute concerning the terms of this Agreement. Therefore, the parties have a duty to cooperate to resolve all such disputes as rapidly as possible on a fair
and equitable basis. If any dispute or claim arising under this Agreement cannot be readily resolved within thirty (30) days of the receipt of written notice by a party of a dispute, then the Chief Executive Officer of ASOthera and the VP of
Business Development & Technology Transfer of CSHL (or their respective designees) will meet to review and attempt to resolve the dispute within sixty (60) days. A copy of the Agreement, agreed upon facts (and areas of disagreement),
and concise summary of the basis for each side’s contentions will be provided to both such officers who will review the same, confer and attempt to reach a mutual resolution of the issue. In the event the parties are unable to resolve the
dispute within such sixty (60) day period, then either party may seek any relief or remedy available to it. Notwithstanding the foregoing, nothing in this Section 13.9 will be construed to waive any rights or timely
performance of any obligations existing under the Agreement. 

  

					
		  		  	
		  	21	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 13.10 Entire Agreement. This Agreement, together with the Sponsored Research Agreement and the
Consulting Agreement, embodies the entire understanding between the parties relating to the subject matter hereof and supersedes all prior understandings and agreements, whether written or oral. This Agreement may not be varied except by a written
document signed by duly authorized representatives of both parties. In the event of a conflict between any provisions of this Agreement, the Sponsored Research Agreement or the Consulting Agreement, the said agreements will be given the following
order of precedence: 
 1. this Agreement; 
 2. the Sponsored
Research Agreement; 
 3. the Consulting Agreement. 
 13.11
Severability. If any provision of this Agreement is held to be invalid or unenforceable by a court of competent jurisdiction, then the remaining provisions of this Agreement will remain in full force and effect. Such invalid or unenforceable
provision will be automatically revised to be a valid and enforceable provision that comes as close as permitted by law to the parties’ original intent. 

13.12 Counterparts. This Agreement may be executed in counterparts, each of which will be deemed an original, but all of which together will constitute
one and the same instrument. 
 *    *    *    *    * 

  

					
		  		  	
		  	22	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 IN WITNESS WHEREOF, the duly authorized representatives of the parties hereby execute this Agreement as of
the Effective Date. 
  

									
	Cold Spring Harbor Laboratory	 		 	ASOthera Pharmaceuticals, Inc.
					
	By:	 	/s/ Teri F. Willey	 		 	By:	 	/s/ Huw M. Nash
	Name:	 	Teri F. Willey	 		 	Name:	 	Huw M. Nash
	Title:	 	V.P. Business Development + Technology Transfer	 		 	Title:	 	CEO
					
	Date:	 	                                     
   	 		 	Date:	 	July 29, 2015

  

					
		  		  	
		  	23	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 Exhibit A 

Licensed Patent Rights 
 KRAINER 06: Targeted
Augmentation of Nuclear Gene Output (“TANGO”) Inventor: Adrian Krainer 
  

																					
	 Application #
	  	Patent #	 	  	Filing Date	 	  	Type	 	  	Status	 	  	Issue Date	 
	 [*]
	  				  	 	10/3/14	 	  	 	Provisional	 	  	 	Filed	 	  			

  

					
		  		  	
		  	24	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 Exhibit B 

Form of Stock Purchase Agreement 

  

					
		  		  	
		  	25	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

 ASOTHERA PHARMACEUTICALS, INC. 

RESTRICTED STOCK PURCHASE AGREEMENT 

This Restricted Stock Purchase Agreement (this “Agreement”) is made and entered into as of July [__], 2015 (the
“Effective Date”) by and between ASOthera Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware (the “Company”), and Cold Spring Harbor Laboratory, a nonprofit New York
State education corporation (the “Purchaser”). 
  

	 	1.	 PURCHASE AND SALE OF SHARES. 

1.1 Certain Definitions. The following terms are defined as follows: 

(a) “Fully Diluted Shares” means, at the relevant time, the total number of shares
of capital stock of the Company represented by (i) all outstanding shares of the common stock of the Company, par value $0.0001 per share (the “Common Stock”); (ii) all shares of Common Stock
issuable upon conversion of outstanding shares of preferred stock of the Company; (iii) all shares of Common Stock directly or indirectly issuable upon exercise of outstanding Company stock options and warrants; and (iv) shares reserved
and available for grant and/or issuance to service providers under an equity incentive plan but unissued. 
 (b)
“Qualified Financing” means the sale in a single transaction or in a series of related transactions of the capital stock of the Company for an aggregate gross purchase price paid to the Company of
no less than $5 million (including, without limitation, the conversion of the principal amount of and accrued interest and any other amounts owing on the promissory notes issued to Apple Tree Partners IV, L.P. (“Apple
Tree”) pursuant to that certain Note Purchase Agreement by and among ASOthera and Apple Tree dated November 13, 2014 and that certain Note Purchase Agreement by and among ASOthera and Apple Tree dated June 12,
2015). 
 1.2 Sale and Issuance of Shares. On the Effective Date and subject to the terms and conditions of this
Agreement, Purchaser hereby purchases from the Company, and the Company hereby sells to the Purchaser, 1,640,608 shares of Common Stock (the “Shares”) for the consideration described in that certain License Agreement between
the Company and the Purchaser of even date herewith (the “License Agreement”). Purchaser acknowledges and agrees that the issuance of the Shares to Purchaser shall be in full satisfaction of the rights of Purchaser set forth
in Section 4.1 and Section 4.2 of the License Agreement, and that following the issuance of such Shares, the Company shall have no further obligations to Purchaser pursuant to Section 4.1 or Section 4.2 of the License Agreement.

 2. CLOSING. 

2.1 Deliveries by Purchaser. The Purchaser hereby delivers to the Company: 

(a) a duly executed copy of this Agreement; 

  

					
		  		  	
		  	B-1	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

 (b) a duly executed copy of the Joinder Agreement attached hereto as Exhibit
A; 
 (c) a duly executed copy of the Adoption Agreement attached hereto as Exhibit B; and 

(d) a duly executed copy of the License Agreement. 

2.2 Deliveries by the Company. Upon its issuance of the Shares, the Company will issue a duly executed stock
certificate evidencing the Shares in the name of the Purchaser for the number of Shares issued to it pursuant to this Agreement. 

3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company represents and warrants to the Purchaser as follows
as of the Effective Date. 
 3.1 Organization, Good Standing, Corporate Power and Qualification.
The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its business as presently conducted and as proposed to
be conducted. The Company is duly qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify would have a material adverse effect. 

3.2 Authorization. All corporate action required to be taken by the board of directors and stockholders of the
Company in order to authorize the Company to enter into this Agreement, and to issue the Shares, has been taken prior to the Effective Date. All action on the part of the officers of the Company necessary for the execution and delivery of this
Agreement, the performance of all obligations of the Company under this Agreement to be performed as of the Effective Date, and the issuance and delivery of the Shares on the Effective Date has been taken prior to the Effective Date. This Agreement,
when executed and delivered by the Company, shall constitute a valid and legally binding obligation of the Company, enforceable against the Company in accordance with its respective terms except (a) as limited by applicable bankruptcy,
insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or affecting the enforcement of creditors’ rights generally or (b) as limited by laws relating to the availability of specific
performance, injunctive relief, or other equitable remedies. 
 3.3 Valid Issuance of Shares. The Shares, when
issued, sold and delivered in accordance with the terms and for the consideration set forth in this Agreement, will be validly issued, fully paid and nonassessable and free of restrictions on transfer other than restrictions on transfer under this
Agreement, applicable state and federal securities laws and liens or encumbrances created by or imposed by the Purchaser. The Company has consummated a Qualified Financing, and immediately following the issuance of the Shares, the Shares will
represent 4.33% (rounding to the nearest hundredth of a percent) of the Company’s Fully Diluted Shares. Assuming the accuracy of the representations of the Purchaser in Section 4 of this Agreement and subject to the filing of all required
governmental consents and filings, the Shares will be issued in compliance with all applicable federal and state securities laws. 

  

					
		  		  	
		  	B-2	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

 4. REPRESENTATIONS AND WARRANTIES OF PURCHASER. The Purchaser
represents and warrants to the Company as follows as of the Effective Date. 
 4.1 Purchase for Own Account for
Investment. Purchaser is purchasing the Shares on its own account for investment purposes only and not with a view to, or for sale in connection with, a distribution of the Shares within the meaning of the Securities Act of 1933, as
amended (the “1933 Act”). Purchaser has no present intention of selling or otherwise disposing of all or any portion of the Shares and no one other than Purchaser has any beneficial ownership of any of the Shares. 

4.2 Access to Information. Purchaser has had access to all information regarding the Company and its present and
prospective business, assets, liabilities and financial condition that Purchaser reasonably considers important in making the decision to purchase the Shares, and Purchaser has had ample opportunity to ask questions of the Company’s
representatives concerning such matters and this investment. 
 4.3 Understanding of Risks. Purchaser is fully
aware of: (a) the highly speculative nature of the investment in the Shares; (b) the financial hazards involved; (c) the lack of liquidity of the Shares and the restrictions on transferability of the Shares (e.g., that
Purchaser may not be able to sell or dispose of the Shares or use them as collateral for loans); (d) the qualifications and backgrounds of the management of the Company; and (e) the tax consequences of investment in the Shares. 

4.4 Purchaser’s Qualifications; Accredited Investor. Purchaser has a preexisting business relationship with
the Company and/or certain of its officers and/or directors of a nature and duration sufficient to make Purchaser aware of the character, business acumen and general business and financial circumstances of the Company and/or such officers and
directors. By reason of Purchaser’s business or financial experience, Purchaser is capable of evaluating the merits and risks of this investment, has the ability to protect its own interests in this transaction and is financially capable of
bearing a total loss of this investment. In addition, Purchaser is an “accredited investor” as that term is used in Regulation D promulgated under the 1933 Act. 

4.5 No General Solicitation. At no time was Purchaser presented with or solicited by any publicly issued or
circulated newspaper, mail, radio, television or other form of general advertising or solicitation in connection with the issuance of the Shares. 

4.6 Compliance with Securities Laws. Purchaser understands and acknowledges that, in reliance upon the
representations and warranties made by Purchaser herein, the Shares are not being registered with the Securities and Exchange Commission (“SEC”) under the 1933 Act, but instead are being issued under an exemption or
exemptions from the registration and qualification requirements of the 1933 Act or other applicable state securities laws which impose certain restrictions on Purchaser’s ability to transfer the Shares. 

  
 B-3 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

 4.7 Restrictions on Transfer. Purchaser understands that
Purchaser may not transfer any Shares unless such Shares are registered under the 1933 Act and qualified under applicable state securities laws or unless, in the opinion of counsel to the Company, exemptions from such registration and qualification
requirements are available. Purchaser understands that only the Company may file a registration statement with the SEC or applicable state securities commissioners and that the Company is under no obligation to do so with respect to the Shares.
Purchaser has also been advised that exemptions from registration and qualification may not be available or may not permit Purchaser to transfer all or any of the Shares in the amounts or at the times proposed by Purchaser. 

4.8 Rule 144. In addition, Purchaser has been advised that SEC Rule 144
promulgated under the 1933 Act, which permits certain limited sales of unregistered securities, is not presently available with respect to the Shares and, in any event, requires that the Shares be held for a minimum of six months, and in certain
cases one year, after they have been issued (within the meaning of Rule 144), before they may be resold under Rule 144. Purchaser understands that Rule 144 may indefinitely restrict transfer of the Shares so long as Purchaser remains
an “affiliate” of the Company and certain information about the Company (as defined in Rule 144) is not publicly available. 

5. COMPLIANCE WITH GOVERNANCE AGREEMENTS. Purchaser agrees to be bound by and comply with (i) the Right of First
Refusal and Co-Sale Agreement dated as of July 15, 2015, by and among the Company, the Investors listed on Schedule A thereto, and the Key Holders listed on Schedule B thereto (the
“Right of First Refusal and Co-Sale Agreement”), (ii) the Voting Agreement, dated as of July 15, 2015, by and among the Company, the Investors listed on Schedule A thereto,
and the Key Holders listed on Schedule B thereto (the “Voting Agreement”), and (iii) the transfer restrictions set forth in Section 6 and Section 7 below. All future transferees of all or part of the
Shares shall receive and hold such Shares subject to (i) the Right of First Refusal and Co-Sale Agreement, (ii) the Voting Agreement, and (iii) the transfer restrictions set forth in
Section 6 and Section 7 below. 
 6. MARKET STANDOFF AGREEMENT. Purchaser agrees in connection with
any registration of the Company’s securities under the 1933 Act that, upon the request of the Company or the underwriters managing any registered public offering of the Company’s securities, Purchaser will not sell or otherwise
dispose of any shares of capital stock of the Company without the prior written consent of the Company or such underwriters, as the case may be, for such period of time (not to exceed one hundred eighty (180) days) after the effective date of
such registration requested by such managing underwriters and subject to all restrictions as the Company or the managing underwriters may specify for shareholders generally. Purchaser further agrees to enter into any agreement reasonably required by
the underwriters to implement the foregoing and that such underwriters are express third-party beneficiaries of this Section 6. 

  

					
		  		  	
		  	B-4	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

 7. RESTRICTIVE LEGENDS AND STOP-TRANSFER ORDERS. 

7.1 Legends. Purchaser understands and agrees that the Company will place the legends set forth below or similar
legends on any stock certificate(s) evidencing the Shares, together with any other legends that may be required by state or federal securities laws, the Company’s certificate of incorporation or bylaws, any other agreement between Purchaser and
the Company or any third party: 
 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES
LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF
COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. 

THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON PUBLIC RESALE AND TRANSFER, INCLUDING A MARKET STANDOFF
RESTRICTION, AS SET FORTH IN A RESTRICTED STOCK PURCHASE AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER. SUCH PUBLIC SALE AND TRANSFER RESTRICTIONS,
INCLUDING THE MARKET STANDOFF RESTRICTION, ARE BINDING ON TRANSFEREES OF THESE SHARES. 
 7.2 Stop-Transfer
Instructions. Purchaser agrees that, to ensure compliance with the restrictions imposed by this Agreement, the Company may issue appropriate “stop-transfer” instructions to its transfer agent, if any, and if the Company
transfers its own securities, it may make appropriate notations to the same effect in its own records. The Company will not be required (a) to transfer on its books any Shares that have been sold or otherwise transferred in violation of any of
the provisions of this Agreement or (b) to treat as owner of such Shares, or to accord the right to vote or pay dividends, to any Purchaser or other transferee to whom such Shares have been so transferred. 

 

	 	8.	 GENERAL PROVISIONS. 

8.1 Notices. Any and all notices required or permitted to be given to a party pursuant to the provisions of this
Agreement will be in writing and will be effective and deemed to provide such party sufficient notice under this Agreement on the earliest of actual receipt or: (a) at the time of personal delivery, if delivery is in person; (b) when sent,
if sent by electronic mail or facsimile during the recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business day (c) one (1) business day after deposit with an express
overnight courier for United States deliveries, or two (2) business days after such deposit for deliveries outside of the United States; or (d) three (3) business days after deposit in the United States mail by certified mail (return
receipt requested) for United States deliveries. All notices for delivery outside the United States will be sent by express courier. All notices not 

  

					
		  		  	
		  	B-5	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

 
delivered personally will be sent with postage and/or other charges prepaid and properly addressed to the party to be notified at the address set forth below the signature lines of this
Agreement or at such other address as such other party may designate by one of the indicated means of notice herein to the other party hereto. A “business day” shall be a day, other than Saturday or Sunday, when the banks in
the city of New York City are open for business. 
 8.2 Further Assurances. The parties agree to execute such
further documents and instruments and to take such further actions as may be reasonably necessary to carry out the purposes and intent of this Agreement. 

8.3 Titles and Headings. The titles, captions and headings of this Agreement are included for ease of reference
only and will be disregarded in interpreting or construing this Agreement. Unless otherwise specifically stated, all references herein to “sections” and “exhibits” will mean “sections” and “exhibits” to this
Agreement. 
 8.4 Governing Law. This Agreement will be governed by and construed in accordance with the laws of
the State of New York, without giving effect to that body of laws pertaining to conflict of laws. 
 8.5 Assignments;
Successors and Assigns. The Company may assign any of its rights and obligations under this Agreement. Any assignment of rights and obligations by any other party to this Agreement requires the Company’s prior written consent.
This Agreement, and the rights and obligations of the parties hereunder, will be binding upon and inure to the benefit of their respective successors, assigns, heirs, executors, administrators and legal representatives. 

8.6 Entire Agreement. This Agreement and the documents referred to herein constitute the entire agreement and
understanding of the parties with respect to the subject matter of this Agreement, and supersede all prior understandings and agreements, whether oral or written, between or among the parties hereto with respect to the specific subject matter
hereof. 
 8.7 Amendment and Waivers. This Agreement may be amended only by a written agreement executed by the
Company and the Purchaser. Any amendment effected in accordance with this section will be binding upon all parties hereto and each of their respective successors and assigns. No delay or failure to require performance of any provision of this
Agreement shall constitute a waiver of that provision as to that or any other instance. No waiver granted under this Agreement as to any one provision herein shall constitute a subsequent waiver of such provision or of any other provision herein,
nor shall it constitute the waiver of any performance other than the actual performance specifically waived. 
 8.8
Severability. If any provision of this Agreement is determined by any court or arbitrator of competent jurisdiction to be invalid, illegal or unenforceable in any respect, such provision will be enforced to the maximum extent
possible given the intent of the parties hereto. If such clause or provision cannot be so enforced, such provision shall be stricken from this Agreement and the remainder of this Agreement shall be enforced as if such invalid, illegal or
unenforceable clause or provision had (to the extent not enforceable) never been contained in this Agreement. Notwithstanding the forgoing, if the value of this Agreement based upon the substantial benefit of the bargain for any party is materially
impaired, which determination as made by the presiding court or arbitrator of competent jurisdiction shall be binding, then both parties agree to substitute such provision(s) through good faith negotiations. 

  

					
		  		  	
		  	B-6	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

 8.9 Counterparts; Facsimile Signatures. This Agreement may be
executed in any number of counterparts, each of which when so executed and delivered will be deemed an original, and all of which together shall constitute one and the same agreement. This Agreement may be executed and delivered by facsimile and,
upon such delivery, the facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other party. 

[Signature page follows] 

  

					
		  		  	
		  	B-7	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

 IN WITNESS WHEREOF, the parties have caused this Restricted Stock Purchase Agreement
to be executed by their duly authorized representatives, each as of the Effective Date. 
  

			
	 COMPANY:

	
	 ASOTHERA PHARMACEUTICALS,
INC.

			
		
	By:	 	 

			
	Its:	 	 

			
	 Address:
	 	 
	 

  

			
	 PURCHASER:

	
	 COLD SPRING HARBOR
LABORATORY

			
		
	By:	 	 

			
	Its:	 	 

			
	 Address:
	 	 
	 

  

					
		  		  	
		  	B-8	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

 Exhibit C 

Client and Billing Agreement Form 
 Cold
Spring Harbor Laboratory (“CSHL”), a New York non-profit education corporation doing business at 1 Bungtown Road, Cold Spring Harbor, NY 11724; and ASOthera Pharmaceuticals, Inc.
(“ASOthera”), a corporation doing business at _______________ have entered into a License Agreement with respect to Licensed Patents; 
 On behalf
of CSHL, ASOthera has retained the services of _________ (“Law Firm”), with offices at _________________________________, to prepare, file and prosecute the pending patent applications constituting Licensed Patents and to maintain the
patents that issue thereon; 
 CSHL, ASOthera and Law Firm, intending to formalize their business relationships, agree as follows: 

 

	 	1.	 CSHL is the sole owner of Licensed Patents 

 

	 	2.	 ASOthera is the licensee of CSHL’s interest in Licensed Patents. 

 

	 	3.	 CSHL will have and will maintain an attorney-client relationship with Law Firm in furtherance of efforts to
secure and maintain Licensed Patents. 

  

	 	4.	 To assist CSHL in these efforts, CSHL agrees to have Law Firm and ASOthera interact directly with each other on
all patent prosecution and patent maintenance matters related to the Licensed Patents and to copy CSHL on all correspondence related thereto. Subject to the right of CSHL to review and to make recommendations as provided in this paragraph, ASOthera
will be responsible for providing Law Firm with instructions on all prosecution and maintenance matters. ASOthera and Law Firm agree to use all reasonable efforts to notify CSHL in writing at least thirty (30) days prior to the due date or
deadline for any action which would substantively affect the pending status of any patent application within Licensed Patents, the maintenance of any granted patent within the Licensed Patents, CSHL’s right to file any continuing application or
foreign counterpart application based on the Licensed Patents, or the breadth of any claim within the Licensed Patents; provided that ASOthera will not be required to notify CSHL in advance of oral claim negotiations with patent offices. In any
case, ASOthera must give CSHL written notice of any final decision regarding the action to be taken or not to be taken on such matters and will consider any CSHL recommendations in good faith before instructing Law Firm to implement the decision.

  

					
		  		  	
		  	26	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

	 	5.	 Law Firm’s legal services relating to the Licensed Patents will be performed on behalf of CSHL. Law Firm
will invoice ASOthera directly for all work relating to the filing, prosecution and maintenance of Licensed Patents and must provide copies of all invoices to CSHL. ASOthera is responsible for the payment of all charges and fees so invoiced by Law
Firm. ASOthera will pay invoices directly to Law Firm and copy CSHL on each payment. 

  

	 	6.	 To clarify each party’s position with regard to prosecution and maintenance of Licensed Patents, ASOthera
will notify Law Firm in writing of all decisions to authorize the performance of any desired service(s), which will be subject to CSHL right to review and to make recommendations, as provided in paragraph 4 above. Any such recommendations by CSHL
must be promptly communicated in writing to Law Firm and ASOthera. 

  

	 	7.	 This agreement represents the complete understanding of each of the undersigned parties as to the client and
billing arrangements defined herein. Additions or deletions to Licensed Patents will be identified in Appendix A will become effective only by written addendum to Appendix A. All such additions or deletions of individual patents or applications
filed in the US, or as foreign counterparts thereof are considered to be within the terms of this client and billing agreement. 

  

	 	8.	 Notices and copies of all correspondence relating to Licensed Patents should be sent to the following:

  

			
	 TO CSHL:
	  	TO ASOTHERA:
	 Office for Business Development
	  	
	 & Technology Transfer
	  	
	 Cold Spring Harbor Laboratory
	  	
	 1 Bungtown Road
	  	
	 Cold Spring Harbor, NY 11724
	  	TO LAW FIRM:

  

					
		  		  	
		  	27	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

									
	ACCEPTED AND AGREED TO:	 		 	
			
	COLD SPRING HARBOR LABORATORY	 		 	ASOTHERA

									
					
	By:	 	 	 		 	By:	 	 

									
					
	Name:	 	 	 		 	Name:	 	 

									
					
	Title:	 	 	 		 	Title:	 	 

									
					
	Date:	 	 	 		 	Date:	 	 

  

			
	LAW FIRM
		
	By:	 	 

			
		
	Name:	 	 

			
		
	Title:	 	 

			
		
	Date:	 	 

  

					
		  		  	
		  	28	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

 Exhibit D 

Capitalization Table 
 [*]

  

					
		  		  	
		  	29	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

 Exhibit E 

Consulting Agreement 

  

					
		  		  	
		  	30	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 CONSULTING AGREEMENT 

This Agreement is made as of October 24, 2014 between ASOthera Pharmaceuticals, Inc. (the “Company”) and Adrian
Krainer, PhD (the “Consultant”), an employee of the Cold Spring Harbor Laboratory (“CSHL”). The Company is engaged in scientific research relating to the development of antisense-based drugs, therapies, diagnostic and research
tools, products, services and intellectual property (the “Field”). The Consultant has experience in the Field, and the Company seeks to benefit from the Consultant’s expertise by retaining the Consultant as a consultant. The
Consultant wishes to perform consulting services in the Field for the Company. Accordingly, the Company and the Consultant agree as follows: 

1. Services. 
 (a) The
Consultant shall provide consulting services to the Company with respect to matters related to the Field. The Consultant’s services for the Company shall consist only of the exchange of ideas and provision of advice; the Consultant shall not
direct or conduct research for or on behalf of the Company except pursuant to the terms of the Sponsored Research Agreement dated October 24, 2014 by and between Company and CSHL (the “Sponsored Research Agreement”). More
specifically, Consultant shall (i) serve on the Company’s scientific advisory board and attend scientific advisory board meetings; (ii) provide general scientific advice regarding the Company’s products or services, the general
direction of its research program, recruitment of personnel, and techniques used in research in the Field; and (iii) advise on the Company’s efforts to produce, develop, and market one or more specific products or services in the Field.
The Consultant’s services shall be rendered at CSHL, the Company’s offices, or any location that is mutually agreeable to Consultant and Company. 

(b) The Company acknowledges that the Consultant is a CSHL employee and is subject to CSHL’s policies, including policies concerning
consulting, conflicts of interest, and intellectual property. Any conflict between the policies of CSHL and this Agreement shall be decided in a manner consistent with CSHL policies. The Company acknowledges and agrees that nothing in this Agreement
shall affect the Consultant’s obligations to CSHL, the Consultant’s research on behalf of CSHL, the Consultant’s ability to submit and publish the results of CSHL research, or research collaborations in which the Consultant is a
participant, and that this 

  

					
	Page 39 of 8	  		  	
		  	E-39	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 
Agreement shall have no effect upon transfers (by way of license or otherwise) to third parties of materials or intellectual property developed in whole or in part by the Consultant as a CSHL
employee. Consultant hereby certifies that Consultant has no outstanding agreement or obligation that is in conflict with, or that would preclude Consultant from complying with, this Agreement. Subject to written waivers that may be provided by the
Company upon request, which shall not be unreasonably withheld, Consultant agrees that, during the term of this Agreement, Consultant will not directly or indirectly provide any services in the Field to any other business or commercial entity on
programs or products that compete with a program or product of the Company. Without limiting the foregoing, Consultant agrees to use his best efforts (i) to segregate Consultant’s services performed under this Agreement from
Consultant’s work done for any such third party or for CSHL so as to minimize any questions of disclosure of, or rights under, any inventions, (ii) to notify the CEO of the Company if at any time the Consultant believes that such questions
may result from his performance under this Agreement and (iii) to assist the Company in fairly resolving any questions in this regard which may arise. The services performed hereunder will not be conducted on time that is required to be devoted
to CSHL or any other third party. 
 2. Compensation. 

The consideration described in Exhibit A constitutes the full consideration for the consulting services to be provided by the Consultant to
the Company. 
 3. Confidentiality. 

(a) The Consultant may disclose to the Company any information that the Consultant would normally freely disclose to other members of the
scientific community at large, whether by publication, by presentation at seminars, or in informal scientific discussions. However, the Consultant shall not disclose to the Company information that (i) is proprietary to CSHL and (ii) is
not generally available to the public, except through formal technology transfer procedures. Without limiting the generality of the foregoing, the Consultant may disclose to the Company any information that is subject to the Option Agreement dated
October 24, 2014 between CSHL and Company (the “Option Agreement”) or any license agreement that may be entered pursuant to the terms of the Option Agreement (the “License Agreement”) or the Sponsored Research Agreement.

  

					
	Page 40 of 8	  		  	
		  	E-40	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 (b) In providing consulting services to the Company pursuant to this Agreement, the
Consultant may acquire information that pertains to the Company’s products, processes, equipment, programs, developments, or plans and that is both (i) disclosed or made known by the Company to the Consultant and (ii) either
identified as “confidential” by the Company at any time or which due to its nature or the circumstances of its disclosure, a person exercising reasonable business judgment would understand to be confidential or proprietary (collectively,
“Company Confidential Information”). In addition, “Company Confidential Information” includes information that is generated by the Consultant (whether alone or with others) (A) during the course of performing consulting
services for the Company under this Agreement and (B) outside the course of the Consultant’s activities as an CSHL employee or member of CSHL’s scientific staff. The Consultant agrees not to disclose any Company Confidential
Information to third parties or to use any Company Confidential Information for any purpose other than performance of consulting services pursuant to this Agreement, without the prior written consent of the Company. The obligations of Consultant
under this paragraph 3(b) will continue for a period of five (5) years after the expiration or termination of this Agreement. 
 (c)
“Company Confidential Information” does not include information that: (i) is or later becomes available to the public through no breach of this Agreement by the Consultant; (ii) is obtained by the Consultant from a third party
who had the legal right to disclose the information to the Consultant; or (iii) is already in the possession of the Consultant on the date this Agreement becomes effective. In addition, nothing in this Agreement shall restrict Consultant from
disclosing Company Confidential Information to the extent it is required to be disclosed by law, government regulation, or court order, provided that the Consultant takes reasonable steps to provide the Company with sufficient prior notice to allow
the Company to consent to the disclosure or seek a protective order. In addition, Company Confidential Information does not include information generated by the Consultant (whether alone or with others) unless the Consultant generated the
information (A) during the course of performing consulting services for the Company under this Agreement and (B) outside the course of the Consultant’s activities as an CSHL employee or member of CSHL’s scientific staff.
Upon the Company’s request, the Consultant shall return to the Company any or all Company Confidential Information that is in writing or is otherwise in physical or tangible form. 

  

					
	Page 41 of 8	  		  	
		  	E-41	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 4. Intellectual Property. 

(a) Recognizing that the Consultant is a full time employee of CSHL, the CSHL policy regarding ownership of employee Intellectual Property
will apply and the Company shall have no rights by reason of this Agreement in any publication, invention, discovery, improvement, or other intellectual property whatsoever, whether or not publishable, patentable, or copyrightable, which is
developed as a result of a program of research financed, in whole or in part, by funds provided by, through or under the control of CSHL (collectively, “CSHL Intellectual Property”). The Company also acknowledges and agrees that it will
enjoy no priority or advantage as a direct result of the consultancy created by this Agreement in gaining access, whether by license or otherwise, to any proprietary information or intellectual property that arises from any research undertaken by
the Consultant in the Consultant’s capacity as a CSHL employee or member of CSHL’s scientific staff except as provided for under the Sponsored Research Agreement, the Option Agreement or any License Agreement. 

(b) It is understood and agreed that CSHL’s interest in any inventions or know-how that are
conceived, developed or reduced to practice solely or jointly by Consultant in connection with Consultant’s performance of services under this Agreement will constitute Patent Period Inventions or Licensed
Know-how (as the case may be) under the Option Agreement and any license agreement that may be entered into pursuant to the terms thereof. 

5. Defense and Indemnification. 

The Company agrees, at its sole expense, to defend CSHL and Consultant against, and to indemnify and hold CSHL and Consultant harmless from,
any liability, claim, judgment, cost, expense, damage, deficiency, loss, or obligation, of any kind or nature (including without limitation reasonable attorneys’ fees and other costs and expenses of defense) relating to a claim or suit by a
third party against CSHL or Consultant, either arising from this Agreement, the Consultant’s performance of services for the Company under this Agreement, or any Company products or services which result from the Consultant’s performance
of services under this Agreement, except for any of the same resulting from Consultant’s gross negligence, willful misconduct or failure to comply with applicable law. 

  

					
	Page 42 of 8	  		  	
		  	E-42	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 6. Term and Termination. 

(a) Unless terminated earlier under paragraph 6(b), below, this Agreement shall be for a term of five years. This Agreement may be extended
by mutual written agreement of Consultant and Company. 
 (b) Without limiting any rights which either party to this Agreement may have by
reason of any default by the other party, each party reserves the right to terminate this Agreement at its convenience by written notice given to the other party. Such termination shall be effective upon the date not earlier than 90 days following
the date of such notice as shall be specified in said notice. 
 (c) Paragraphs 3, 4, 5, 6(c), and 7 hereof shall survive termination of
this Agreement. In addition, termination of this Agreement shall not affect either (i) the Company’s obligation to pay for services previously performed by the Consultant or expenses reasonably incurred by the Consultant for
which the Consultant is entitled to reimbursement under paragraph 2, above, or (ii) the Consultant’s continuing obligations to the Company under paragraphs 3 and 4, above. 

7. Miscellaneous. 
 (a)
This Agreement shall inure to the benefit of and be binding upon the respective heirs, executors, successors, representatives, and assigns of the parties, as the case may be; provided, however, the obligations hereunder of each party to the other
are personal and may not be assigned without the express written consent of such other party. 
 (b) The relationship created by this
Agreement shall be that of independent contractor, and the Consultant shall have no authority to bind or act as agent for the Company or its employees for any purpose. 

(c) The Company may use the Consultant’s name, and in doing so may cite the Consultant’s relationship with CSHL, so long as any
such usage (i) is limited to reporting factual events or occurrences only, and (ii) is made in a manner that could not reasonably constitute an endorsement, promotion or advertisement of the Company or of any Company program, product or
service. However, the Company shall not use the Consultant’s name or CSHL’s name in any press release, or quote the Consultant in any company materials, or otherwise use the Consultant’s name or CSHL’s name in a manner not
specifically permitted by the preceding sentence, unless in each case the Company obtains in advance CSHL’s written consent, and, in the case of the use of the Consultant’s name, the Consultant’s consent as well. 

  

					
	Page 43 of 8	  		  	
		  	E-43	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 (d) Notice given by one party to the other hereunder shall be in writing and deemed to have
been properly given if personally delivered or sent by registered or certified mail or overnight express courier (prepaid), addressed as follows: 
  

					
		  	To Consultant:	  	Dr. Adrian Krainer
		  		  	c/o Cold Spring Harbor Laboratory
		  		  	One Bungtown Road
		  		  	Cold Spring Harbor, NY 11724
			
		  		  	With a copy to:
			
		  		  	Cold Spring Harbor Laboratory
		  		  	One Bungtown Road
		  		  	Cold Spring Harbor, NY 11724
		  		  	Attention: Vice President, Business Development
		  		  	 & Technology Transfer

			
		  	To Company:	  	ASOthera Pharmaceuticals, Inc.
		  		  	4 Washington Street
		  		  	Lexington, MA 02421
		  		  	Attention: Huw Nash

 (e) This Agreement supersedes all prior or contemporaneous agreements and discussions relating to the subject
matter hereof and constitutes the entire agreement between the Company and the Consultant with respect to the subject matter of this Agreement. The Company and the Consultant agree that any amendment of this Agreement (including, without limitation,
any extension of its term or any change in the consideration set forth above to be provided to the Consultant hereunder) or any other departure from the terms or conditions hereof must be signed by the Consultant and an authorized representative of
the Company, and also is subject to CSHL’s prior written approval. Notwithstanding the foregoing, in the event of a conflict between any provisions of this Agreement, the Option Agreement, any license agreement that may be entered pursuant to
the terms of the Option Agreement or the Sponsored Research Agreement, the said agreements will be given the following order of precedence: 

1. the Option Agreement and any license agreement that may be entered pursuant to the terms thereof; 

  

					
	Page 44 of 8	  		  	
		  	E-44	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 2. the Sponsored Research Agreement; and 

3. this Agreement. 
 (f) If any
provision of this Agreement affecting the rights or property of CSHL is adjudicated to be invalid, unenforceable, contrary to, or prohibited under applicable laws or regulations of any jurisdiction, this Agreement shall terminate as of the date such
adjudication is effective. If any other provision of this Agreement is adjudicated to be invalid, unenforceable, contrary to, or prohibited under applicable laws or regulations of any jurisdiction, such provision shall be severed and
the remaining provisions shall continue in full force and effect. 
 (g) The Consultant and the Company acknowledge that (i) the
Consultant is entering into this Agreement in the Consultant’s individual capacity and not as an employee or agent of CSHL, (ii) CSHL is not a party to this Agreement and has no liability or obligation hereunder, and (iii) CSHL is an
intended third-party beneficiary of this Agreement and certain provisions of this Agreement are for CSHL’s benefit and are enforceable by CSHL in its own name. 

IN WITNESS WHEREOF, the parties have executed this Agreement effective as of the date first stated above. 

 

			
	ASOthera Pharmaceuticals, Inc.
		
	By:	 	/s/ Huw M. Nash
	Name:	 	Huw M. Nash
	Title:	 	Chief Executive Officer
	Date:	 	November 18, 2014

  

	
	Adrian R. Krainer
	Adrian Krainer, PhD
	Date: 11/18/14

  

					
	Page 45 of 8	  		  	
		  	E-45	  	

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 Exhibit A 

Compensation 
 The Company
shall pay the Consultant as follows: a total of $100,000 per year payable in monthly installments of $8,333.33 per month. No monthly invoice to the Company from the Consultant will be required for the aforementioned compensation. In addition to the
foregoing amount, the Company shall promptly reimburse the Consultant for all reasonable expenses incurred by the Consultant in providing consulting services under this Agreement, provided that any single expense above $1,000 is approved in advance
by the Company and provided that the Consultant submits an invoice detailing such reasonable expenses, such invoices to be paid within 30 days by the Company. 

  

					
	Page 46 of 8	  		  	
		  	E-46EX-10.9

 EXHIBIT 10.9 

CONFIDENTIAL 
 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN
THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 

LICENSE AGREEMENT 

BETWEEN 
 UNIVERSITY OF
SOUTHAMPTON 
 AND 

ASOTHERA PHARMACEUTICALS, INC. 

This License Agreement (“Agreement”) is made effective as of the date of last signature as written below (the
“Effective Date”) by and between University of Southampton, whose administrative offices are at University Road, Highfield, Southampton, SO17 1BJ (“University”) and ASOthera Pharmaceuticals, Inc., a
corporation organized and existing under the laws of Delaware (“ASOthera”), having an office at 3 Preston Court, Suite 102, Bedford, MA 01730. 

RECITALS 
 WHEREAS,
ASOthera and University are parties to that certain Option Agreement (“Option Agreement”) dated June 1, 2015 pursuant to which University granted ASOthera an exclusive option to negotiate to acquire a license to practice
certain patents and know-how; 
 WHEREAS, ASOthera has exercised such option in accordance with the
terms of the Option Agreement; 
 WHEREAS, consistent with the parties’ rights and obligations pursuant to the Option Agreement,
ASOthera desires to obtain from University, and University desires to grant to ASOthera, a license to practice such patents and know-how in accordance with the terms and conditions of this Agreement; 

NOW, THEREFORE, in consideration of the mutual benefits to be derived hereunder, and intending to be legally bound, the parties agree as
follows: 
  

	1.	 DEFINITIONS 

1.1. “Affiliate” means, with respect to a person or entity, a legal entity that is controlling, controlled by or under common
control with that person or entity. For purposes of this Section 1.1, the word “control” means (1) the direct or indirect ownership of more than fifty percent (50%) of the outstanding voting securities of a
legal entity, (2) the right to receive fifty percent (50%) or more of the profits or earnings of a legal entity, (3) the right to determine the policy decisions of a legal entity, or (4) fifty percent (50%) or greater management
control over a legal entity. 
 1.2. “Commercially Reasonable Efforts” means efforts that would be employed by the relevant
party in connection with researching, developing, and commercializing its own products of similar market potential at a similar stage of product life, taking into account the apparent attributes of the product, the competitiveness of the relevant
marketplace, the proprietary positions of third parties, regulatory structures, including the likelihood of obtaining regulatory approval, and the anticipated profitability of such product. For clarity, the exertion of Commercially Reasonable
Efforts will not require that a party actually accomplish the applicable objectives or tasks. 

  
 1 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

			
	 CONFIDENTIAL
	  	ASOthera 2016
	 RIS Ref: 14108
	  	

  

 1.3. “Confidential Information” means all information, inventions,
developments, discoveries, software, know-how, methods, techniques, formulae, data, processes, and other proprietary ideas, whether or not patentable, that a party (the “Disclosing Party”)
identifies as confidential or proprietary at the time it is delivered or communicated to the other party (the “Receiving Party”). 

1.4. “Event of Force Majeure” means an unforeseeable act that wholly prevents a party from performing one or more of its
material duties under the Agreement and that was outside of the reasonable control of the party. An Event of Force Majeure includes acts of war or of nature, insurrection and riot, labor strikes, and delays imposed by regulatory agencies. 

1.5. “Field” means all applications, including but not limited to diagnostic, therapeutic and/or vaccine applications; 

1.6. “Licensed Know-how” means all technical information, materials and know-how which relate to the Licensed Patents which have been developed or are owned by, proprietary to and/or controlled by University, which are secret, substantial and which are necessary for or useful to the
development and commercialization of Licensed Products. The Licensed Know-how shall not include any information, materials and/or know-how which are generally
ascertainable from publicly available information. 
 1.7. “Licensed Patents” means University’s interest in the patent
applications and patents listed in Part 1 of Exhibit A, and in each case, any divisionals, continuations, continuations-in-part, and all patents issuing
therefrom, and any and all extensions, reexaminations, reissues and corresponding foreign patent rights. 
 1.8. “Licensed
Products” means any product for use in the Field that if made, used, sold, offered for sale or imported absent the license granted hereunder would infringe a Valid Claim, or that uses or incorporates the Licensed Know-how. 
 1.9. “Net Sales” shall have the meaning given to it in Section 4.7(a).

 1.10. “Phase 1 Trial” means a human clinical trial that is intended to initially evaluate the safety and/or
pharmacological effect of a Licensed Product in subjects or that would otherwise satisfy requirements of 21 C.F.R. 312.21(a), or its non-U.S. equivalent. 

1.11. “Phase 3 Trial” means a human clinical trial in any country, the results of which could be used to establish safety and
efficacy of a Licensed Product as a basis for an new drug application before the United States Food and Drug Administration (FDA) or would otherwise satisfy requirements of 21 C.F.R. 312.21(c), or its non-U.S.
equivalent. 
 1.12. “Qualifying Costs” means: [*] 

1.13. “Royalty Term” means the period commending on the Effective Date and ending upon the expiration of the last to expire
of the Licensed Patents or expiration of marketing exclusivity granted by a regulatory authority, whichever occurs later. 

  
 2 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

			
	 CONFIDENTIAL
	  	ASOthera 2016
	 RIS Ref: 14108
	  	

  

 1.14. “Sale” means any bona fide transaction with a Third Party for which
consideration is received or expected for the sale, use, lease, transfer or other disposition of a Licensed Product made following the receipt of final marketing approval from the applicable health regulatory authorities in the country of sale, and
a Sale is deemed completed at the time that ASOthera, or its Affiliate, sublicensee or sublicensee’s Affiliate invoices, ships or receives payment for a Licensed Product, whichever occurs first. For the avoidance of doubt, the sale, use, lease,
transfer or other disposition of Licensed Products between or among ASOthera, its Affiliates, its sublicensees or its sublicensees’ Affiliates for the purpose of resale to a Third Party will not be considered a Sale under this Agreement. 

1.15. “Sublicense” means any right granted, license given or agreement entered into, by ASOthera to or with any other person
or entity, under or with respect to or permitting any use of any of the Licensed Patents or otherwise permitting the development, manufacture, marketing, distribution and/or sale of Licensed Products (regardless of whether such grant of rights,
license given or agreement entered into is referred to or is described as a sublicense). For clarity and notwithstanding the foregoing, “Sublicense” does not include: 

(a) a grant by ASOthera as part of a Sale of a Licensed Product to a Third Party of the implied license (1) to use such Licensed Product
or (2) to resell such Licensed Product, provided that the only consideration (whether monetary or non-monetary) received by ASOthera, or any Affiliate of ASOthera, in connection with such grant is the
fair market value of the Licensed Product sold; or 
 (b) any agreement in which ASOthera grants its Affiliate the right to perform or
exercise some or all of ASOthera’s rights and/or obligations under this Agreement, as long as such Affiliate does not pay ASOthera any consideration (in any form) actually for such grant. 

1.16. “Sublicense Revenue” means all compensation or consideration of any kind received pursuant to a Sublicense, and includes
any payments made by a Third Party to ASOthera on behalf of a sublicensee; provided, however, that Sublicense Revenue specifically excludes: 

(a) any royalties or profit share amounts attributable to sales of Licensed Products (provided that such sales form the basis of royalties paid
to University); 
 (b) payments specifically committed in the Sublicense to cover actual costs incurred or to be incurred by ASOthera
(including equipment purchases and full-time equivalent personnel actually provided by ASOthera) in the research and development of Licensed Products which are the subject matter of the Sublicense; 

(c) reimbursement of payments paid by ASOthera to University for milestone events or amounts incurred with respect to the filing, prosecution
or maintenance of any Licensed Patents; 
 (d) loans or other debt obligations (any amounts which are forgiven will be deemed Sublicense
Revenue); 
 (e) amounts received from any Third Party for the purchase of equity at fair market value; 

  
 3 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

			
	 CONFIDENTIAL
	  	ASOthera 2016
	 RIS Ref: 14108
	  	

  

 (f) securities of an Affiliate received from an Affiliate that are not provided in exchange
for the grant of a Sublicense; and 
 (g) amounts received in consideration of the sale of substantially all of the business or assets of
ASOthera or any of its Affiliates. 
 1.17. “Third Party” means any person or entity other than University and ASOthera and
its Affiliates, sublicensees and sublicensees’ Affiliates. For the avoidance of doubt, when the term “third party” is used in this Agreement without capitalization it means any person or entity other than University and ASOthera. 

1.18. “Valid Claim” means (a) a claim of an issued and unexpired patent included within any of the Licensed Patents,
which has not been held permanently revoked, unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction in an unappealed or unappealable decision, and which has not been admitted to be invalid or
unenforceable through reissue or disclaimer or otherwise or (b) a claim of a pending patent application included within any of the Licensed Patents that has not been withdrawn, canceled, or disclaimed or has not been pending for more than five
years. 
  

	2.	 LICENSE 

2.1. License Grant. University hereby grants ASOthera: 

(a) an exclusive, worldwide, royalty-bearing, sublicensable (through multiple tiers, subject to the conditions of
Section 2.3) license under the Licensed Patents, and 
 (b) a
non-exclusive, worldwide, royalty-free license under the Licensed Know-how, 

in each case to research, develop, manufacture, make, have made, use, offer for sale, sell, import and commercialize Licensed Products in the Field. 

2.2. Reservation of Rights by University. 

(a) Notwithstanding the licenses granted to ASOthera under Section 2.1, University reserves the worldwide right to
practice, and to permit other non-profit non-commercial entities to practice (under a specific written agreement with University), the Licensed Patents for all non-profit non-commercial research purposes and teaching purposes without any payment therefor; provided that any materials provided to any third party non-profit non-commercial entity will be furnished pursuant to industry standard confidentiality and material transfer agreements that comply with this Agreement. 

(b) Subject to Section 6, University and its faculty and employees shall have the right to publish, any information
relating to its research activities; provided however that for a period of 2 years from the Effective Date, University shall provide ASOthera the opportunity to review each proposed manuscript, abstract or any other proposed disclosure describing
the Licensed Patents or the University technology, know-how and intellectual property the subject of the Licensed Patents (60) days prior to their submission for publication or other proposed disclosure.
If ASOthera believes patentable subject matter or Confidential Information relating to the Licensed Patents is disclosed in the manuscript or other disclosure and so notifies University, or if such submission for publication or other disclosure
would cause the loss of U.S. or foreign patent rights in which ASOthera has an interest, said publication will be withheld for a reasonable period of time, not to exceed four (4) months, to allow for filing of the applicable patent application.

  
 4 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

			
	 CONFIDENTIAL
	  	ASOthera 2016
	 RIS Ref: 14108
	  	

  

 2.3. Sublicense Conditions. ASOthera’s right to grant Sublicenses under the
licenses granted to ASOthera under Section 2.1 is subject to each of the following conditions: 
 (a) ASOthera may
not grant Sublicenses except with the prior written approval of University, which shall not be unreasonably withheld. Such prior written approval shall not be required if such sublicensee’s primary business is healthcare-related, including but
not limited to the development, manufacture or sale of pharmaceutical, biopharmaceutical or diagnostic products or services. 
 (b) ASOthera
will enter into a written Sublicense agreement with each sublicensee, which is subject to University’s rights under Section 2.2 and requires the payment by the sublicensee to ASOthera of royalties on Net Sales in a
manner which will enable ASOthera to comply with Section 4.4. 
 2.4. University shall promptly following the
Execution Date and periodically during the Term thereafter deliver to ASOthera the Licensed Know-how, including the technology the subject of the Licensed Patents and the Licensed Know-how and all related drawings, specifications, procedures and manuals. In addition, University shall provide expertise and support through consultancy [*], for up to [*]; after which additional consulting
activities shall be reimbursed under a separate consulting agreement or sponsored research agreement (as applicable). The parties acknowledge and agree that, if the parties enter into a sponsored research agreement with respect to research to be
conducted by University which is fully funded by ASOthera, such sponsored research agreement would provide that any improvements to the Licensed Patents that are conceived or reduced to practice solely or jointly by or on behalf of University in the
performance of such sponsored research agreement, and any technical information, materials and know-how which relate to the Licensed Patents that is developed solely or jointly by or on behalf of University in
the performance of such sponsored research agreement, and any patents and patent applications claiming any of the foregoing, shall, without altering the amounts payable under this Agreement, constitute Licensed Patents or Licensed Know-How (as the case may be) under this Agreement. 
  

	3.	 DILIGENCE 

3.1. Development Plans and Progress Reports. Within [*] after the first anniversary of the [*], and [*] thereafter throughout the Term,
ASOthera will submit to University a written development plan and progress report documenting the technical and relevant business development of Licensed Products in order to demonstrate ASOthera’s capability to bring Licensed Products to
commercialization. 
 3.2. Diligence Plan. ASOthera intends to build a pharmaceutical company with a drug discovery pipeline based on
antisense oligonucleotides that utilize certain University technologies. ASOthera will use Commercially Reasonable Efforts to design antisense oligonucleotides based on the University technology, [*]. If hit oligonucleotides are identified, ASOthera
will use Commercially Reasonable Efforts to perform lead optimization to improve the following properties: 1) [*], 2) [*], 3) [*], 4) [*], and 5) [*]. If, in ASOthera’s sole discretion, at least one oligonucleotide satisfies the criteria in the
foregoing subclauses 1) – 5), then ASOthera will use Commercially Reasonable Efforts to perform pre-clinical activities to identify at least 

  
 5 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

			
	 CONFIDENTIAL
	  	ASOthera 2016
	 RIS Ref: 14108
	  	

  

 
one (1) oligonucleotide that possesses suitable in vitro and in vivo efficacies, PK and safety properties for clinical development, and at least one (1) investigational
new drug application/IND filing will be submitted to the FDA (or a non-U.S. regulatory authorities), for approval of an initial Phase 1 Trial (or phase 1/2 clinical trial). 

3.3. Diligence Milestones. ASOthera will use Commercially Reasonable Efforts to achieve each milestone specified below (each, a
“Diligence Milestone”) for at least (1) one Licensed Product: 
 (a) [*]; 

(b) [*]; 
 (c) [*]; 

(d) [*]. 
 3.4. Failure to
Achieve a Diligence Milestone. If ASOthera believes it will be unable to achieve a Diligence Milestone, then ASOthera will notify University. If such Diligence Milestone has an agreed date, then ASOthera will notify University no later than [*]
before the target date for fulfillment of such Diligence Milestone. 
 (a) If ASOthera has been using Commercially Reasonable Efforts (as
demonstrated by reasonable supporting documentation) to achieve such Diligence Milestone, University will grant ASOthera a [*] extension of any such Diligence Milestone. 

(b) At the end of such extension, if such Diligence Milestone has not been achieved and ASOthera has been using Commercially Reasonable Efforts
(as demonstrated by reasonable supporting documentation) to achieve such Diligence Milestone, ASOthera will present a revised development plan outlining its plan to achieve such Diligence Milestone. If such plan is acceptable to University, such
acceptance not to be unreasonably withheld, University agrees that the date to achieve a given Diligence Milestone can be extended for an additional [*] provided ASOthera pays an extension fee of [*] (“Extension Fee”). 

(c) The non-achievement of a Diligence Milestone after a [*] extension period allowed by payment of
such an Extension Fee may constitute a breach of the Agreement. It will not be a breach of the Agreement, and University may not withhold its consent to any extension, where the failure to do so is as a result of the occurrence of an Event of Force
Majeure during the Term. 
 (d) It is understood and agreed that the foregoing obligations may be satisfied by ASOthera directly, or by its
sublicensees. 
  

	4.	 FEES AND ROYALTIES 

4.1. Upfront Payment. Promptly following the Effective Date, ASOthera will pay to University £55,000 (fifty-five thousand sterling
pounds) [*] paid to University by ASOthera under the Option Agreement). 

  
 6 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

			
	 CONFIDENTIAL
	  	ASOthera 2016
	 RIS Ref: 14108
	  	

  

 4.2. Minimum Annual Payment. ASOthera will pay to University the following amounts:

  

	 	•	 	 [*]; 

  

	 	•	 	 [*]; 

  

	 	•	 	 [*]; 

  

	 	•	 	 [*]; and 

  

	 	•	 	 [*]. 

Each such payment under this Section 4.2 will be due within [*] of the applicable anniversary of the Effective Date and is
nonrefundable; however, each such payment will be fully creditable against any royalties or milestone payments under this Agreement that accrue in the same year. 

4.3. Milestone Payments. ASOthera will pay to University the applicable milestone payment listed in the table below for achievement of
the applicable milestone event by the first Licensed Product that if made, used, sold, offered for sale or imported absent the license granted hereunder would infringe a Valid Claim of any of the Licensed Patents: 

 

			
	 Milestone Event
	  	Milestone Payment For First Licensed
Product to Achieve the Milestone Event
	[*]	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]

 In no event will a milestone payment be paid more than once, even if one or more additional Licensed Products subsequently
achieve the same milestone event. 
 4.4. Earned Royalties. During the Royalty Term, ASOthera will pay University the following
royalties in U.S. dollars: 
 (a) [*] on Net Sales of Licensed Products whose composition of matter falls within one or more Valid Claims of
any of the Licensed Patents; and 
 (b) [*] on Net Sales of Licensed Products whose composition of matter does not fall within one or more
Valid Claims of any of the Licensed Patents but (1) that otherwise fall within one or more Valid Claims of any of the Licensed Patents or (2) that previously fell within one or more Valid Claims of any of the Licensed Patents and are sold
or offered for sale during a period of market exclusivity granted by a regulatory authority to ASOthera (or any of its Affiliates, sublicensees or sublicensees’ Affiliates) with regard to such Licensed Product. 

Except as otherwise set forth in Subsection 4.4(b)(2) above, no royalty will be due on Net Sales of Licensed Products whose manufacture, use, sale,
offer for sale or importation does not, absent the License granted hereunder, infringe a Valid Claim. 
 Only one royalty will be owed for a Licensed
Product regardless of how many Valid Claims cover such Product. 

  
 7 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

			
	 CONFIDENTIAL
	  	ASOthera 2016
	 RIS Ref: 14108
	  	

  

 4.5. Exclusion from Royalties. No royalty will be due with respect to commercially
reasonable quantities of units of Licensed Products used solely for clinical trials, other internal research or development purposes, in a compassionate use program, or as samples or promotional goods. 

4.6. Stacking Protection. In the event any Licensed Product includes other patented/patentable (or previously patented) technology of a
Third Party in addition to the Licensed Patents, for which ASOthera, its Affiliates or sublicensees are required to pay royalties to any Third Party in order to commercialise and exploit the Licensed Product , then ASOthera may offset an amount
equal to [*] of any third-party royalty payments owed with respect to sale of a Licensed Product against the royalty payments that are due to University for such Licensed Product; provided that in no event, will the royalty payments to University be
reduced by more than [*] of the amount otherwise due to University with respect to such Licensed Product (i.e., no less than [*] and [*], respectively). 

4.7. Net Sales; Combination Products. 

(a) “Net Sales” means the total amount invoiced for each Sale by ASOthera or its Affiliates, sublicensees or
sublicensees’ Affiliates, less Qualifying Costs directly attributable to a Sale and actually included in the invoiced amount and borne by ASOthera or its Affiliates, sublicensees or sublicensees’ Affiliates. 

(b) Where a Licensed Product is sold as part of a group of other products or services that is not covered by the Licensed Patents or the
Licensed Know-how, (“Other Products”) the net sales of such group will be allocated between the Licensed Product and Other Products in a consistent and equitable manner to be mutually agreed between
the parties and that reflects the contribution of the Licensed Product relative to the Other Products for the amounts invoiced for such group of products. Provided always that as a minimum the fair market value for the Licensed Products should be
payable. ASOthera shall provide its proposed allocation calculation together with information in relation to any combination deal and of other products as reasonably requested by the University to enable the University to evaluate the appropriate
allocation relative to the Licensed Products. 
 (c) If the parties are unable to agree upon the appropriate combination product allocation
and or fair market value under Section 4.7(b) and provided ASOthera has provided the requested information to the University the matter shall be referred to escalation to their respective executives as provided at Section 12.10. In
the event the Parties are not successful in resolving the dispute through escalation to their respective executives as provided for in Section 12.10, then either Party may request arbitration of such dispute as provided in
this Section 4.7.(c). The decision of the arbitrator shall be final and binding on the parties. The arbitration will be conducted in London, England in accordance with the terms set forth in this Section and such other terms as are set forth in
the rules of the International Chamber of Commerce (ICC) Rules of Arbitration. The arbitration shall be conducted by one (1) arbitrator mutually agreed upon by the parties. If the parties are not able to mutually agree on an arbitrator within
twenty (20) business days after the date that a party requests arbitration as provided in this Section, then the arbitrator will be selected as provided in the ICC Rules of Arbitration within ten (10) business days thereafter. The
arbitrator will have expertise and experience with arbitration in the nature described in this Section. The Parties shall meet equally in the fees of arbitrator and for the proceedings however each Party will bear their own costs in relation to
their participation in and preparation for arbitration including their own legal fees. 

  
 8 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

			
	 CONFIDENTIAL
	  	ASOthera 2016
	 RIS Ref: 14108
	  	

  

 4.8. Sublicense Revenue Sharing. For each Sublicense granted by ASOthera, ASOthera
will pay to University [*] of all Sublicense Revenue. For the avoidance of doubt, Net Sales of any Licensed Product by any sublicensee or sublicensee’s Affiliate are subject to ASOthera’s royalty obligation to University. 

 

	5.	 REPORTS AND PAYMENTS. 

5.1. Royalty Reports. Within [*] after the end of each calendar year following first commercial Sale of a Licensed Product, ASOthera
will deliver to University a report, certified by the chief financial officer of ASOthera, detailing the calculation of all royalties and fees due to University for such calendar year. The report will include, at a minimum: 

(a) [*]; 
 (b) [*]; 

(c) [*]; 
 (d) [*]; 

(e) [*]; and 
 (f) [*]. 

5.2. Payments. All amounts paid by ASOthera to University under this Agreement will be paid as set forth in
Section 5.2. ASOthera will pay all royalties and fees due to University under Sections 4.3, 4.4 and 4.7 within [*] after the end of the calendar year in which the royalties or fees accrue. The
University shall charge Value Added Tax (VAT) or General Sales Tax (CST) or equivalent, in addition, where applicable, at the prevailing rate. For avoidance of doubt any withholding tax or other tax payable by the University to US Federal or State
tax authorities shall be the responsibility of the University. The University shall be responsible for ensuring it makes payment of any VAT, corporation or income taxes to the UK tax authorities on any revenues received from ASOthera. Before any
payments are paid to University under this Agreement, University shall timely provide to ASOthera a properly completed applicable W-8 form and other forms and documents that ASOthera may reasonably request as
required in determining ASOthera’s withholding obligation under applicable tax law. 
 5.3. Records. ASOthera will maintain, and
will cause its Affiliates and sublicensees to maintain, complete and accurate books and records to verify Sales, Net Sales, and all of the royalties, fees, and other payments payable under this Agreement. The records for each calendar year will be
maintained for at least [*] after submission of the applicable report required under Section 5.1. 
 5.4. Audit
Rights. Upon reasonable prior written notice to ASOthera, ASOthera and its Affiliates and sublicensees will provide University and, subject to reasonable obligations of confidentiality, its accountants with access to all of the books and records
required by Section 5.3 to conduct a review or audit of Sales, Net Sales, and all of the royalties, fees, and other payments payable under this Agreement. Access will be made available: 

(a) during normal business hours; 

  
 9 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

			
	 CONFIDENTIAL
	  	ASOthera 2016
	 RIS Ref: 14108
	  	

  

 (b) in a manner reasonably designed to facilitate University’s review or audit without
unreasonable disruption to ASOthera’s business; and 
 (c) no more than once each calendar year during the Term and for a period of
three (3) years thereafter. The review or audit may cover a period of not more than [*] before the first day of the calendar year in which the review or audit is requested. 

ASOthera will promptly pay to University the amount of any underpayment determined by the review or audit. If the review or audit determines that ASOthera has
underpaid any royalty payment by [*] or more, then ASOthera will also promptly pay the out of pocket costs and expenses of the University or its accountants or auditors in connection with the review or audit. 

5.5. Place of Payment. All payments by ASOthera are payable to “University of Southampton” and will be made to the following
addresses: 
  

			
	 By Electronic Transfer:
	  	 By Check:

	[*]	  	Made payable to the ‘University of Southampton’ and crossed a/c payee only. Send to Income Office, Finance Department, University of Southampton, Highfield Campus, Southampton SO17 1BJ

  

	6.	 CONFIDENTIALITY 

6.1. Confidentiality Obligation. The Receiving Party will maintain in confidence and not disclose to any Third Party any Confidential
Information. The Receiving Party will use the Confidential Information only for the purposes of performing its obligations and exercising its rights under this Agreement. The Receiving Party will ensure that its employees and its Affiliates and
sublicensees have access to the Confidential Information only on a need to know basis and are obligated in writing to abide by the Receiving Party’s obligations under this Article 6. 

6.2. Exceptions. The obligations under Section 6.1 will not apply to: 

(a) information that is known to the Receiving Party prior to the time of disclosure, to the extent evidenced by written records; 

(b) information that is disclosed to the Receiving Party by a Third Party that has the right to make such disclosure; 

(c) information that is independently developed by the Receiving Party without use of the Confidential Information, to the extent evidenced by
written records; or 
 (d) information that becomes part of the public domain through no fault of the Receiving Party. 

Nothing in this Agreement will be deemed to restrict the Receiving Party from disclosing Confidential Information to the extent required by any order,
subpoena, law, statute or regulation; provided that Receiving Party uses reasonable efforts to give the Disclosing Party reasonable advance notice of such required disclosure in order to enable the Disclosing Party to prevent or limit such
disclosure. 

  
 10 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

			
	 CONFIDENTIAL
	  	ASOthera 2016
	 RIS Ref: 14108
	  	

  

 6.3. ASOthera shall mention University in any publication relating to the Licensed Patents or
the Licensed Know-how as an originator of the underlying technology in accordance with accepted norms for scientific publication. 
  

	7.	 TERM AND TERMINATION 

7.1. Term. The term of this Agreement will begin on the Effective Date and, unless terminated earlier, will continue in full force and
effect on a Licensed Product-by-Licensed Product and country-by-country basis until the
expiration of the last-to-expire Valid Claim covering the making, using, selling, offering to sell or importing of such Licensed Product in such country or until the
expiration of market exclusivity granted by a regulatory authority in such country, whichever occurs later (“Term”). Unless this Agreement is terminated by either party pursuant to Section 7.2 or
Section 7.3, ASOthera will have a perpetual royalty-free non-exclusive license under the Licensed Know-how following expiration of the Term. 

7.2. Termination by University. University may terminate this Agreement effective upon written notice to ASOthera if: 

(a) ASOthera materially breaches this Agreement and does not cure such breach within ninety (90) days after written notice of such breach;
notwithstanding the foregoing, in the event of a good faith dispute with respect to the existence of a material breach, the applicable cure period will be tolled until such time as the dispute is finally resolved in accordance with the dispute
resolution mechanism specified in Sections 12.9 and 12.10; 
 (b) ASOthera commits any act of bankruptcy, becomes insolvent, is unable
to pay its debts as they become due, files a petition under any bankruptcy or insolvency act or has any such petition filed against it which is not dismissed within ninety (90) days; 

(c) ASOthera repeatedly fails to make indisputably required payments to University within thirty (30) calendar days after such payments
are due. 
 7.3. Termination by ASOthera. Notwithstanding anything contained herein to the contrary, ASOthera has the right to
terminate this Agreement at any time in its sole discretion by giving thirty (30) days advance written notice to University. 
 7.4.
Effect of Termination. If this Agreement is terminated for any reason (excluding, for the avoidance of doubt, expiration of the Term under Section 7.1): 

(a) the Licenses granted to ASOthera under Section 2.1 shall terminate immediately; 

(b) ASOthera and all its Affiliates will cease making, having made, using, importing, selling and offering for sale all Licensed Products; 

(c) ASOthera will pay to University all amounts owed to University through the date of termination of this Agreement within [*] days of such
date of termination; 
 (d) in the case of termination under Section 7.2, all duties of University and all rights
(but not all duties) of ASOthera under this Agreement will immediately terminate without further action required by either University or ASOthera; 

  
 11 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

			
	 CONFIDENTIAL
	  	ASOthera 2016
	 RIS Ref: 14108
	  	

  

 (e) each party will return to such other party or destroy all Confidential Information of
such other party (and, for the avoidance of doubt, ASOthera will return to University or destroy all copies of drawings, specifications and manuals describing the Licensed Knowhow that were provided by University to ASOthera; and 

(f) any Sublicense granted prior to such termination will survive as a direct license with University and the sublicensee will automatically
become a direct licensee of University with respect to the rights originally sublicensed to the sublicensee; provided that: (i) such sublicensee is not in breach of its Sublicense; (ii) such sublicensee agrees to comply with all of the
terms of this Agreement to the extent applicable to the rights originally sublicensed to such sublicensee; and (iii) such sublicensee agrees to pay directly to University such sublicensee’s payments under this Agreement to the extent
applicable to the rights sublicensed to such sublicensee. ASOthera agrees that it will confirm the foregoing in writing at the request and for the benefit of University and/or the sublicensee. 

7.5. Surviving Rights and Obligations. Termination of this Agreement will not affect the rights and obligations of the parties accrued
prior to termination hereof. The provisions of Articles 4, 5, 6, 9, 11 and 12 and Sections 7.4, 7.5, 10.3, 10.4 and 10.5 will survive the termination of this Agreement for any reason in accordance with their respective terms. 

 

	8.	 PATENT MAINTENANCE AND REIMBURSEMENT 

8.1. Patent Maintenance. University will control the preparation, prosecution and maintenance of the Licensed Patents and the selection
of patent counsel, with input from ASOthera. ASOthera will have the right to assume the prosecution and maintenance of the Licensed Patents in University’s name and at ASOthera’s expense, provided ASOthera and University enter into a
Client and Billing Agreement with mutually-acceptable patent counsel in the form attached hereto as Exhibit B. 
 8.2. Patent
Reimbursement. Within [*] after the Effective Date, ASOthera will reimburse University for all historically accrued, un-reimbursed attorneys’ fees, expenses, official fees and all other charges
accumulated prior to the Effective Date incident to the preparation, prosecution and maintenance of the Licensed Patents, excluding any of such fees, expenses and charges already paid by ASOthera under the Option Agreement. ASOthera will reimburse
University for all documented attorneys’ fees, expenses, official fees and all other charges incident to the preparation, prosecution and maintenance of the Licensed Patents within [*] after ASOthera’s receipt of invoices for such fees,
expenses, and charges unless agreed otherwise in a Client and Billing Agreement. 
  

	9.	 INFRINGEMENT 

9.1. Notice. ASOthera and University will notify each other promptly of any infringement of the Licensed Patents that may come to their
attention. ASOthera and University will consult each other in a timely manner concerning any appropriate response to the infringement. 

9.2. ASOthera Prosecution. ASOthera may prosecute an action against a Third Party to protect the Licensed Patents, including an
infringement action. The expenses of such action, including attorneys’ fees, expert fees and all other costs and expenses of the litigation, including appeals, settlement processes and alternative dispute mechanisms, will be borne by ASOthera.

  
 12 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

			
	 CONFIDENTIAL
	  	ASOthera 2016
	 RIS Ref: 14108
	  	

  

 University will execute all necessary and proper documents and take all other appropriate
actions to allow ASOthera to institute and prosecute the action. 
 Any award paid by a Third Party as a result of such action (whether by
way of settlement or otherwise) will first be applied toward reimbursement of attorneys’ fees, expert fees and all other costs and expenses of the litigation, including appeals, settlement processes and alternative dispute mechanisms, and the
excess, if any, will be retained by ASOthera; provided that ASOthera shall pay the University in accordance with Clause 4.8 on sums received after deduction of attorneys’ fees or costs and expenses of the litigation. 

9.3. University Prosecution. If ASOthera, without University’s consent (not to be unreasonably withheld), does not institute such
action against a Third Party, University will have the right but not the obligation to institute an action. Such consent of University may not be withheld where ASOthera provides a reasonable enforcement strategy which involves pursuing other
infringers first. If University elects to prosecute such action, then financial recoveries will be retained by University in their entirety. 

9.4. Cooperation. In any litigation under this Article 9, either party, at the request and expense of the
other party, will cooperate to the fullest extent reasonably possible. This Section 9.4 will not be construed to require either party to undertake any activities, including legal discovery, at the request of any third
party, except as may be required by lawful process of a court of competent jurisdiction. 
  

	10.	 REPRESENTATIONS; DISCLAIMER; LIMITATION OF LIABILITIES 

10.1. University Representation. University hereby represents to ASOthera that: 

(a) it has all requisite corporate power, right and authority to enter into and perform its obligations under this Agreement; 

(b) this Agreement constitutes its valid and binding obligation enforceable in accordance with its terms, and the University as far as it can
reasonably be aware has all rights necessary to license to ASOthera the rights licensed under this Agreement; 
 (c) its execution and
delivery of this Agreement, and compliance with the terms hereof, do not and will not conflict with or result in a breach of any terms of, or constitute a default under, any agreement, obligation or instrument to which it is a party or by which it
is bound; 
 (d) to University’s knowledge as of the Effective Date, there are no inventions that have been conceived or reduced to
practice solely or jointly by University prior to the Effective Date that are dominated by or dominate any patent claims of UK patent application numbers [*] and [*] 

(e) no third party has notified University of any liens, claims or encumbrances on the Licensed Patents that would affect University’s
ability to grant the licenses contained in this Agreement under the Licensed Patents and the Licensed Knowhow. 

  
 13 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

			
	 CONFIDENTIAL
	  	ASOthera 2016
	 RIS Ref: 14108
	  	

  

 10.2. ASOthera Representation. ASOthera hereby represents to University that: 

(a) it is a corporation duly organized, validly existing and in good standing under the laws of Delaware; 

(b) it has all requisite corporate power, right and authority to enter into and perform its obligations under this Agreement; 

(c) this Agreement constitutes its valid and binding obligation enforceable in accordance with its terms; and 

(d) its execution and delivery of this Agreement, and compliance with the terms hereof, do not and will not conflict with or result in a breach
of any terms of, or constitute a default under, any agreement, obligation or instrument to which it is a party or by which it is bound. 

10.3. Disclaimer. The Licensed Patents and Licensed Know-how are provided on an “as
is” basis. Except as explicitly set forth in Section 10.1, University makes no representations or warranties, express or implied, including but not limited to any warranty of merchantability, fitness for a particular
purpose, validity or non-infringement. University will not be liable to ASOthera, its Affiliates, sublicensees or sublicensees’ Affiliates, or the successors or assigns of any of them, or any Third Party
with respect to any claim arising from use of the Licensed Patents or Licensed Know-how or the development, testing, manufacture, use or sale of Licensed Products, in each case by ASOthera, its Affiliates,
sublicensees or sublicensees’ Affiliates. 
 10.4. Except with respect to breach of Section 6
(Confidentiality), in no event will either party be liable to the other party, or its Affiliates, sublicensees, or sublicensees’ Affiliates, or any Third Party, for any consequential, incidental, special or indirect damages (including, but not
limited to, any lost profits or business interruption) based on activity arising out of or related to this Agreement, whether pursuant to a claim of breach of contract or any other claim of any type. 

10.5. Assumption of Risk. As between ASOthera (and its Affiliates, sublicensees and sublicensees’ Affiliates) and University,
ASOthera and its Affiliates, sublicensees and sublicensees’ Affiliates hereby assume the entire risk as to the performance, safety and efficacy of any Licensed Product. 
  

	11.	 INDEMNIFICATION 

11.1. Indemnification. ASOthera will defend, indemnify, and hold harmless University from and against any and all liability, loss,
damage, action, claim, or expense suffered or incurred by the University, its staff or students (“Indemnified Parties”), including attorneys’ fees and expenses (collectively, “Liabilities”), arising out of or
resulting from any Third Party claim arising out of or resulting from (i) the development, manufacture, sale or use of the Licensed Products of ASOthera, its Affiliates, sublicensees, sublicensees’ Affiliates; or (ii) any personal
injury arising from ASOthera’s, its Affiliates’, sublicensees’ and sublicensees’ Affiliates’ negligence. However, the foregoing will not apply to the extent any such Liabilities result or arise from the negligence, willful
misconduct, violation of applicable law, or breach of this Agreement by University. 

  
 14 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

			
	 CONFIDENTIAL
	  	ASOthera 2016
	 RIS Ref: 14108
	  	

  

 11.2. Procedure. The obligation of ASOthera to indemnify, defend and hold harmless
under this Article 11 will be contingent upon timely notification by University to ASOthera of the claim or action; the tender by University to ASOthera of full control over the conduct and disposition of the claim or action; and reasonable
cooperation by University in the defense of the claim or action. ASOthera will not settle or compromise any claim or action giving rise to Liabilities in any manner that imposes any restrictions or obligations on University without University’s
prior written consent (not to be unreasonably withheld). 
 11.3. Insurance. ASOthera shall maintain, during the Term, commercial
general liability insurance with reputable and financially secure insurance carriers to cover the activities of ASOthera under this Agreement. 
  

	12.	 ADDITIONAL PROVISIONS 

12.1. Assignment. No rights hereunder may be assigned by either party, directly or by merger or other operation of law, without the
express written consent of the other party, which consent will not be unreasonably withheld or delayed; except that either party may, without such consent, assign this Agreement to any Affiliate, and ASOthera may assign this Agreement without such
consent in connection with a merger, consolidation, change of control or a sale of all or substantially all of ASOthera’s assets to which this Agreement relates if such assignee’s primary business is healthcare-related, including but not
limited to the development, manufacture or sale of pharmaceutical, biopharmaceutical or diagnostic products or services. Any prohibited assignment of this Agreement or the rights hereunder will be null and void. No assignment will relieve the
assigning party of responsibility for the performance of any accrued obligations which it has prior to such assignment. Subject to the foregoing, this Agreement will be binding upon and will inure to the benefit of the parties and their permitted
assigns. 
 12.2. Waiver. A waiver by either party of a breach or violation of any provision of this Agreement will not constitute or
be construed as a waiver of any subsequent breach or violation of that provision or as a waiver of any breach or violation of any other provision of this Agreement. 

12.3. Independent Contractors. The parties are independent contractors. Nothing contained in this Agreement is intended to create an
agency, partnership or joint venture between the parties. At no time will either party make commitments or incur any charges or expenses for or on behalf of the other party. 

12.4. Compliance with Laws. ASOthera must comply with all prevailing laws, rules and regulations that apply to its activities or
obligations under this Agreement. 
 12.5. ASOthera will comply at all times with the relevant anti-bribery and anti-corruption laws in any
and all countries it operates including the Foreign & Corrupt Practices Act and the UK Bribery Act 2010 failure to do so will be deemed a material breach of this Agreement. 

12.6. Ethical and regulatory approvals. ASOthera will ensure it obtains all necessary ethical and regulatory approvals necessary prior
to the conduct of any clinical trial on or marketing and sale of any Licensed Product. 
 12.7. Patent Marking. Prior to the issuance
of patents falling within the definition of Licensed Patents, ASOthera shall mark all Licensed Products made, sold, offered for sale, imported, or otherwise disposed of by ASOthera under the license granted in this Agreement with the words
“Patent Pending,” and following the issuance of one or more patents, with the numbers of such patents. ASOthera shall cause its Affiliates, and its sublicensees and its sublicensees’ Affiliates to comply with the marking requirements
of this Section12.7. 

  
 15 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

			
	 CONFIDENTIAL
	  	ASOthera 2016
	 RIS Ref: 14108
	  	

  

 12.8. Notice. Notices under this Agreement will be in writing and sent by public
courier and addressed as follows: 
 If to University: 

University of Southampton 

University Road, Highfield, 

Southampton, SO17 1BJ 
 United
Kingdom 
 Attention: Director Research & Innovation Services 

If to ASOthera: 
 ASOthera
Pharmaceuticals, Inc. 
 3 Preston Court 

Suite 102 
 Bedford, MA
01730 Attention: Huw Nash, CEO 
 With a copy (which shall not constitute notice) to: 

Fenwick & West 
 1191
Second Avenue 
 10th Floor 

Seattle, WA 98101 
 Attention:
Effie Toshav, Esq. 
 12.9. Governing Law; Jurisdiction. This Agreement will be governed by and construed in accordance with the laws
of England and Wales, without regard to principles relating to conflicts of law. Subject to Section 12.10, the English courts will have exclusive jurisdiction over the parties with respect to any dispute or controversy
between them arising under or in connection with the Agreement; except that either party may bring proceedings seeking an injunction or other equitable relief in any jurisdiction. 

12.10. Dispute Resolution. The parties understand and appreciate that their long-term mutual interest will be best served by a rapid and
fair resolution of any claims or disputes that may arise under this Agreement or from any dispute concerning the terms of this Agreement. Therefore, the parties have a duty to cooperate to resolve all such disputes as rapidly as possible on a fair
and equitable basis. If any dispute or claim arising under this Agreement cannot be readily resolved within fifteen (15) days of the receipt of written notice by a party of a dispute, then the Senior Vice President of ASOthera and the Dean of
the Faculty of Medicine of the University (or their respective designees) will meet to review and attempt to resolve the dispute within fifteen (15) days. If such dispute or claim cannot be resolved as aforesaid, then the Chief Executive
Officer of ASOthera and the PVC Research & Enterprise of the University (or their respective designees) will meet to review and attempt to resolve the dispute within a further thirty (30) days. A copy of the Agreement, agreed upon
facts (and areas of disagreement), and concise summary of the basis for each side’s contentions will be provided to both such officers who will review the same, confer and attempt to reach a mutual resolution of the issue. In the event the
parties are unable to resolve the dispute within such sixty (60) day period, then either party may, subject to Section 4.7(c), seek any relief or remedy available to it. Notwithstanding the foregoing, nothing in this
Section 12.10 will be construed to waive any rights or timely performance of any obligations existing under the Agreement. 

  
 16 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

			
	 CONFIDENTIAL
	  	ASOthera 2016
	 RIS Ref: 14108
	  	

  

 12.11. Entire Agreement. This Agreement embodies the entire understanding between the
parties relating to the subject matter hereof and supersedes all prior understandings and agreements, whether written or oral. This Agreement may not be varied except by a written document signed by duly authorized representatives of both parties.

 12.12. Severability. If any provision of this Agreement is held to be invalid or unenforceable by a court of competent
jurisdiction, then the remaining provisions of this Agreement will remain in full force and effect. Such invalid or unenforceable provision will be automatically revised to be a valid and enforceable provision that comes as close as permitted by law
to the parties’ original intent. 
 12.13. Counterparts. This Agreement may be executed in original form or by electronic
facsimile or pdf signature, and delivered in any number of counterparts, each of which will be deemed as original and all of which together will constitute one and the same instrument. 

[-signature page follows-] 

  
 17 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

			
	 CONFIDENTIAL
	  	ASOthera 2016
	 RIS Ref: 14108
	  	

  

 IN WITNESS WHEREOF, the duly authorized representatives of the parties hereby execute this
Agreement as of the Effective Date. 
  

									
	University of Southampton	  	                	  	ASOthera Pharmaceuticals, Inc.
					
	By:	  	 [*]
	  		  	By:	  	 /s/ Huw M. Nash

	Name:	  	[*]	  		  	Name:	  	Huw M. Nash
	Title:	  	DIRECTOR	  		  	Title:	  	Chief Executive Officer
		  	RESEARCH & INNOVATION SVC	  		  		  	
	Date:	  	18/4/2016	  		  	Date:	  	April 18, 2016

  
 18 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 EXHIBIT A 

PART 1 - LICENSED PATENTS 

[*] 

  
 19 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 CONFIDENTIAL 

 

 EXHIBIT B 

CLIENT AND BILLING AGREEMENT FORM 

University of Southampton, whose administrative offices are at University Road, Highfield, Southampton, SO17 1BJ
(“University”); and ASOthera Pharmaceuticals, Inc., a company registered in the US under and having its principal place of business at 3 Preston Court, Suite 102, Bedford, MA 01730 (“ASOthera”) have
entered into a License Agreement with respect to Licensed Patents; 
 On behalf of University, ASOthera has retained the services of
                     (“Law Firm”), with offices at
                                         
   , to prepare, file and prosecute the pending patent applications constituting Licensed Patents and to maintain the patents that issue thereon; 

University, ASOthera and Law Firm, intending to formalize their business relationships, agree as follows: 

1. University is the sole owner of Licensed Patents 

2. ASOthera is the licensee of University’s interest in Licensed Patents. 

3. University will have and will maintain an attorney-client relationship with Law Firm in furtherance of efforts to secure and maintain
Licensed Patents. 
 4. To assist University in these efforts, University agrees to have Law Firm and ASOthera interact directly with each
other on all patent prosecution and patent maintenance matters related to the Licensed Patents and to copy University on all correspondence related thereto. Subject to the right of University to review and to make recommendations as provided in this
paragraph, ASOthera will be responsible for providing Law Firm with instructions on all prosecution and maintenance matters. ASOthera and Law Firm agree to use all reasonable efforts to notify University in writing at least [*] days prior to the due
date or deadline for any action which would substantively affect the pending status of any patent application within Licensed Patents, the maintenance of any granted patent within the Licensed Patents, University’s right to file any continuing
application or foreign counterpart application based on the Licensed Patents, or the breadth of any claim within the Licensed Patents; provided that ASOthera will not be required to notify University in advance of oral claim negotiations with patent
offices. In any case, ASOthera must give University written notice of any final decision regarding the action to be taken or not to be taken on such matters and will consider any University recommendations in good faith before instructing Law Firm
to implement the decision. 
 5. Law Firm’s legal services relating to the Licensed Patents will be performed on behalf of University.
Law Firm will invoice ASOthera directly for all work relating to the filing, prosecution and maintenance of Licensed Patents and must provide copies of all invoices to University. ASOthera is responsible for the payment of all charges and fees so
invoiced by Law Firm. ASOthera will pay invoices directly to Law Firm and copy University on each payment. 
 6. To clarify each party’s
position with regard to prosecution and maintenance of Licensed Patents, ASOthera will notify Law Firm in writing of all decisions to authorize the performance of any desired service(s), which will be subject to University right to review and to
make recommendations, as provided in paragraph 4 above. Any such recommendations by University must be promptly communicated in writing to Law Firm and ASOthera. 

  
 20 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

			
	 CONFIDENTIAL
	  	ASOthera 2016
	 RIS Ref: 14108
	  	

  

 7. This Agreement represents the complete understanding of each of the undersigned parties as
to the client and billing arrangements defined herein. Additions or deletions to Licensed Patents will be identified in Appendix A will become effective only by written addendum to Appendix A. All such additions or deletions of individual patents or
applications filed in the US, or as foreign counterparts thereof are considered to be within the terms of this client and billing agreement. 

8. Notices and copies of all correspondence relating to Licensed Patents should be sent to the following: 

TO UNIVERSITY: 
 [*] 

Research and Innovation Services 
 University of Southampton 

Building 37 
 Highfield 

S017 1BJ 
 TO ASOTHERA: 

ASOthera Pharmaceuticals, Inc. 
 3 Preston Court, Suite 102 

Bedford, MA 01730 
 TO LAW FIRM: 

 

                          
                               

                          
                               

                          
                               

                          
                               

  
 21 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
  

			
	 CONFIDENTIAL
	  	ASOthera 2016
	 RIS Ref: 14108
	  	

  

					
	ACCEPTED AND AGREED TO:	 	                    	  	
			
	UNIVERSITY OF SOUTHAMPTON	 		  	ASOTHERA PHARMACEUTICALS, INC.
			
	By:                                     
                                         
                                	 		  	By:                                     
                                         
                          
			
	Name:                                     
                                         
                          	 		  	Name:                                     
                                         
                    
			
	Title:                                     
                                         
                            	 		  	Title:                                     
                                         
                      
			
	Date:                                     
                                         
                            	 		  	Date:                                     
                                         
                      
			
	LAW FIRM	 		  	
			
	By:                                     
                                         
                                	 		  	
			
	Name:                                     
                                         
                          	 		  	
			
	Title:                                     
                                         
                            	 		  	
			
	Date:                                     
                                         
                            	 		  	

  
 22

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}]]